Cardiovascular system | |||||
---|---|---|---|---|---|
Cardiovascular system / Patent ductus arteriosus | |||||
alprostadil | Hospital Only | ||||
ALPROSTADIL
For patent ductus arteriosus - please refer to children's BNF |
|||||
Powder and solvent for solution for injection | |||||
Caverject (Pfizer Ltd) | |||||
Viridal (Advanz Pharma) | |||||
Stick | |||||
Muse (Viatris UK Healthcare Ltd) | |||||
Cutaneous cream | |||||
Vitaros (The Simple Pharma Company UK Ltd) | |||||
dinoprostone | Hospital Only | ||||
Patent ductus arteriosus
For patent ductus arteriosus - please refer to children's BNF |
|||||
Pessary | |||||
Prostin E2 (Pfizer Ltd) | |||||
Vaginal device | |||||
Propess (Ferring Pharmaceuticals Ltd) | |||||
Propess®
WHIPPS CROSS- First line for outpatient induction of labour in low risk women |
|||||
Vaginal gel | |||||
Prostin E2 (Pfizer Ltd) | Hospital Only | ||||
ibuprofen | |||||
Patent ductus arteriosus
For patent ductus arteriosus - please refer to children's BNF |
|||||
Orodispersible tablet | |||||
Nurofen Meltlets (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Modified-release tablet | |||||
Brufen Retard (Viatris UK Healthcare Ltd) | |||||
Chewable capsule | |||||
Nurofen (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Modified-release capsule | |||||
Ibuprofen (Non-proprietary) | |||||
Galprofen Long Lasting (Galpharm International Ltd) | |||||
Nurofen Long Lasting (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Effervescent granules | |||||
Brufen (Viatris UK Healthcare Ltd) | |||||
Oral suspension | |||||
Ibuprofen (Non-proprietary) | |||||
Brufen (Viatris UK Healthcare Ltd) | |||||
Nurofen (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Solution for infusion | |||||
Ibuprofen (Non-proprietary) | |||||
Pedea (Recordati Rare Diseases UK Ltd) | |||||
Oral tablet | |||||
Ibuprofen (Non-proprietary) | |||||
Brufen (Viatris UK Healthcare Ltd) | |||||
Feminax Express (Bayer Plc) | |||||
Nurofen (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Nurofen Express (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Nurofen Joint & Back Pain Relief (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Nurofen Migraine Pain (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Oral capsule | |||||
Ibuprofen (Non-proprietary) | |||||
Flarin (infirst Ltd) | |||||
Nurofen Express (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Cutaneous gel | |||||
Ibuprofen (Non-proprietary) | |||||
Ibugel (Dermal Laboratories Ltd) | |||||
Ibuleve (Diomed Developments Ltd) | |||||
Phorpain (Advanz Pharma) | |||||
Cardiovascular system / Arrhythmias | |||||
Hydroquinidine | Hospital Only | ||||
VERNAKALANT | Hospital Only | ||||
Approved in August 2017 DTC
For rapid conversion of new onset atrial fibrillation ≤ 3 days duration in adult post-cardiac surgery patients
Approved for use in line with approved audit protocol for 100 patients only |
|||||
acebutolol | Off Formulary | ||||
Oral tablet | |||||
Acebutolol (Non-proprietary) | |||||
adenosine | Hospital Only | ||||
ADENOSINE
HOSPITAL ONLY |
|||||
Adenosine 1mg/ml infusion
Adenosine 1mg/ml solution available for stress testing in imaging and measurement of FFR in cath labs |
|||||
Solution for injection | |||||
Adenosine (Non-proprietary) | On Formulary | ||||
Adenocor (Sanofi) | On Formulary | ||||
Solution for infusion | |||||
Adenosine (Non-proprietary) | On Formulary | ||||
Adenoscan (Sanofi) | On Formulary | ||||
amiodarone hydrochloride | On Formulary | ||||
AMIODARONE HYDROCHLORIDE
For supraventricular or ventricular arrythmias.
Please see primary care prescriber information factsheet below for GPs |
|||||
Solution for injection | |||||
Amiodarone hydrochloride (Non-proprietary) | On Formulary | ||||
Amiodarone
INJECTION IS HOSPITAL ONLY |
|||||
Cordarone X (Sanofi) | On Formulary | ||||
Oral tablet | |||||
Amiodarone hydrochloride (Non-proprietary) | |||||
atenolol | On Formulary | ||||
Oral solution | |||||
Atenolol (Non-proprietary) | |||||
Solution for injection | |||||
Tenormin (Atnahs Pharma UK Ltd) | Off Formulary | ||||
Oral tablet | |||||
Atenolol (Non-proprietary) | |||||
Tenormin (Atnahs Pharma UK Ltd) | |||||
atropine sulfate | Hospital Only | ||||
ATROPINE SULFATE
Hospital-Only Drug |
|||||
Solution for injection | |||||
Atropine sulfate (Non-proprietary) | Hospital Only | ||||
Eye drops | |||||
Atropine sulfate (Non-proprietary) | |||||
digoxin | On Formulary | ||||
Oral solution | |||||
Digoxin (Non-proprietary) | |||||
Solution for injection | |||||
Digoxin (Non-proprietary) | Hospital Only | ||||
Solution for infusion | |||||
Digoxin (Non-proprietary) | |||||
Oral tablet | |||||
Digoxin (Non-proprietary) | |||||
disopyramide | On Formulary | ||||
Obstructive hypertrophic cardiomyopathy
Used for symptom relief in obstructive hypertrophic cardiomyopathy under specialist initiation and monitoring |
|||||
Modified-release tablet | |||||
Rythmodan Retard (Neon Healthcare Ltd) | On Formulary | ||||
Oral capsule | |||||
Rythmodan (Neon Healthcare Ltd) | |||||
dronedarone | On Formulary |
NICE TA197 |
|||
DRONEDARONE
Specialist initiation. To be initiated by hospital and continued by GPs. Please see prescribing information sheet below. Dronedarone is recommended as an option for the maintenance of sinus rhythm after successful cardioversion in people with paroxysmal or persistent atrial fibrillation: whose atrial fibrillation is not controlled by first-line therapy (usually including betablockers), that is, as a second-line treatment option and after alternative options have been considered and who have at least 1 of the following cardiovascular risk factors: - hypertension requiring drugs of at least 2 different classes - diabetes mellitus - previous transient ischaemic attack, stroke or systemic embolism - left atrial diameter of 50mm or greater or - age 70 years or older and - who do not have left ventricular systolic dysfunction and - who do not have a history of, or current, heart failure (NYHA Class III/IV).
|
|||||
Oral tablet | |||||
Dronedarone (Non-proprietary) | |||||
Multaq (Sanofi) | |||||
esmolol hydrochloride | Hospital Only | ||||
Solution for injection | |||||
Esmolol hydrochloride (Non-proprietary) | Hospital Only | ||||
Brevibloc (Baxter Healthcare Ltd) | Hospital Only | ||||
Solution for infusion | |||||
Esmolol hydrochloride (Non-proprietary) | |||||
Brevibloc (Baxter Healthcare Ltd) | |||||
flecainide acetate | On Formulary | ||||
FLECAINIDE ACETATE
For injection HOSPITAL ONLY- unlicensed- see medusa for administration For Oral on formulary |
|||||
Oral tablet | |||||
Flecainide acetate (Non-proprietary) | |||||
landiolol hydrochloride | |||||
Powder for solution for infusion | |||||
Rapibloc (AOP Orphan Ltd) | |||||
lidocaine hydrochloride | Hospital Only | ||||
Solution for injection | |||||
Lidocaine hydrochloride (Non-proprietary) | Hospital Only | ||||
Ointment | |||||
Lidocaine hydrochloride (Non-proprietary) | |||||
Spray | |||||
Stud 100 (Pound International Ltd) | |||||
Xylocaine (Aspen Pharma Trading Ltd) | |||||
Approved for IUD insertion in GUM clinics- Hospital Only
Approved at March DTC 2022 |
|||||
Medicated plaster | |||||
Lidocaine hydrochloride (Non-proprietary) | |||||
Ralvo (Grunenthal Ltd) | Off Formulary | ||||
Versatis (Grunenthal Ltd) | Off Formulary | ||||
Versatis®
For treatment of neuropathic pain-see section 4.7.3 |
|||||
Cutaneous cream | |||||
LMX 4 (Ferndale Pharmaceuticals Ltd) | |||||
Vagisil medicated (Combe International Ltd) | |||||
metoprolol tartrate | On Formulary | ||||
METOPROLOL TARTRATE
Initiation for atrial fibrillation, hypertension, secondary prevention of MI, heart failure, stable angina. https://www.nice.org.uk/guidance/ng185 https://www.nice.org.uk/guidance/ng196 https://www.nice.org.uk/guidance/ng133 https://www.nice.org.uk/guidance/cg126
|
|||||
Solution for injection | |||||
Betaloc (Recordati Pharmaceuticals Ltd) | Hospital Only | ||||
Oral tablet | |||||
Metoprolol tartrate (Non-proprietary) | |||||
mexiletine |
NICE TA748 |
||||
Oral capsule | |||||
Mexiletine (Non-proprietary) | |||||
Namuscla (Lupin Healthcare (UK) Ltd) | |||||
nadolol | On Formulary | ||||
Oral tablet | |||||
Nadolol (Non-proprietary) | |||||
propafenone hydrochloride | On Formulary | ||||
Oral tablet | |||||
Propafenone hydrochloride (Non-proprietary) | |||||
Arythmol (Viatris UK Healthcare Ltd) | |||||
propranolol hydrochloride | On Formulary | ||||
PROPRANOLOL HYDROCHLORIDE
Phaechromocytoma (usually started 24 hours after Phenoxybenzamine) |
|||||
PROPRANOLOL for thyrotoxicosis
Symptomatic relief of thyrotoxicosis- |
|||||
Modified-release capsule | |||||
Bedranol SR (Almus Pharmaceuticals Ltd, Sandoz Ltd) | |||||
Propranolol
Whipps Cross: somatic manifestations of acute alcohol withdrawal- see alcohol dependance for more information |
|||||
Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Half Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Oral solution | |||||
Propranolol hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Propranolol hydrochloride (Non-proprietary) | |||||
sotalol hydrochloride | On Formulary | ||||
SOTALOL HYDROCHLORIDE
Specialist initiation. |
|||||
Oral tablet | |||||
Sotalol hydrochloride (Non-proprietary) | |||||
verapamil hydrochloride | On Formulary | ||||
VERAPAMIL HYDROCHLORIDE
For rate controlled angina. https://www.nice.org.uk/guidance/ng196 Stable angina |
|||||
Modified-release tablet | |||||
Half Securon (Viatris UK Healthcare Ltd) | On Formulary | ||||
Securon SR (Viatris UK Healthcare Ltd) | On Formulary | ||||
Vera-Til SR (Accord-UK Ltd, Tillomed Laboratories Ltd) | On Formulary | ||||
Verapress MR (Dexcel-Pharma Ltd) | On Formulary | ||||
Oral solution | |||||
Verapamil hydrochloride (Non-proprietary) | On Formulary | ||||
Solution for injection | |||||
Securon (Viatris UK Healthcare Ltd) | Hospital Only | ||||
Oral tablet | |||||
Verapamil hydrochloride (Non-proprietary) | |||||
vernakalant | Hospital Only | ||||
Local protocol in post surgical patients (SBH)
Approved in August 2017 DTC For rapid conversion of new onset atrial fibrillation ≤ 3 days duration in adult post-cardiac surgery patients
Approved for use in line with approved audit protocol for 100 patients only |
|||||
Solution for infusion | |||||
Brinavess (Advanz Pharma) | |||||
Cardiovascular system / Hypertension | |||||
acebutolol | Off Formulary | ||||
Oral tablet | |||||
Acebutolol (Non-proprietary) | |||||
aliskiren | Off Formulary | ||||
ALISKIREN
Specialist initiation only. |
|||||
Oral tablet | |||||
Rasilez (Noden Pharma DAC) | |||||
amiloride hydrochloride | On Formulary | ||||
AMILORIDE HYDROCHLORIDE
Usually in conjunction with furosemide (co-amilofruse) to maintain K+ while on diuretic treament. |
|||||
Oral solution | |||||
Amiloride hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Amiloride hydrochloride (Non-proprietary) | |||||
amlodipine | On Formulary | ||||
AMLODIPINE
First-line dihydropyridine calcium channel blocker for hypertension. Can be considered for stable angina. |
|||||
Oral suspension | |||||
Amlodipine (Non-proprietary) | Hospital Only | ||||
Liquid prep- hospital only
Liquid prep to be used on the advice of clinical pharmacologist |
|||||
Oral solution | |||||
Amlodipine (Non-proprietary) | |||||
Oral tablet | |||||
Amlodipine (Non-proprietary) | |||||
Istin (Viatris UK Healthcare Ltd) | |||||
amlodipine with valsartan | Off Formulary | ||||
Oral tablet | |||||
Amlodipine with valsartan (Non-proprietary) | |||||
Exforge (Novartis Pharmaceuticals UK Ltd) | |||||
atenolol | On Formulary | ||||
Oral solution | |||||
Atenolol (Non-proprietary) | |||||
Solution for injection | |||||
Tenormin (Atnahs Pharma UK Ltd) | Off Formulary | ||||
Oral tablet | |||||
Atenolol (Non-proprietary) | |||||
Tenormin (Atnahs Pharma UK Ltd) | |||||
azilsartan medoxomil | Off Formulary | ||||
Oral tablet | |||||
Edarbi (Takeda UK Ltd) | |||||
bendroflumethiazide | On Formulary | ||||
Hypertension
NICE hypertension guidance: https://www.nice.org.uk/guidance/ng136 If starting or changing diuretic treatment for hypertension, offer a thiazide-like diuretic, such as indapamide in preference to a conventional thiazide diuretic such as bendroflumethiazide or hydrochlorothiazide. For adults with hypertension already having treatment with bendroflumethiazide or hydrochlorothiazide, who have stable, well-controlled blood pressure, continue with their current treatment. |
|||||
Resistant oedema associated with heart failure
In the management of diuretic resistance, if metolazone is unavailable (only available as import): bendroflumethiazide can be used with loop diuretics for resistant oedema associated with heart failure.
|
|||||
Oral tablet | |||||
Bendroflumethiazide (Non-proprietary) | |||||
bisoprolol fumarate | On Formulary | ||||
BISOPROLOL FUMARATE
First-line for heart failure, atrial fibrillation, secondary prevention of MI and stable angina. https://www.nice.org.uk/guidance/ng136 https://www.nice.org.uk/guidance/ng185 |
|||||
Oral tablet | |||||
Bisoprolol fumarate (Non-proprietary) | |||||
Cardicor (Merck Serono Ltd) | |||||
candesartan cilexetil | On Formulary | ||||
CANDESARTAN CILEXETIL
Can be used if intolerant to ACE Inhibitor - cough for instance. Can be used for Heart Failure, post-MI or hypertension Secondary prevention of MI Guidelines |
|||||
Oral tablet | |||||
Candesartan cilexetil (Non-proprietary) | |||||
Amias (Neon Healthcare Ltd) | |||||
captopril | On Formulary | ||||
Oral solution | |||||
Captopril (Non-proprietary) | |||||
Oral tablet | |||||
Captopril (Non-proprietary) | |||||
carvedilol | On Formulary | ||||
CARVEDILOL
Can be used as second-line beta blocker (after bisoprolol) for heart failure, atrial fibrillation, hypertension, secondary prevention of MI and stable angina. |
|||||
Oral tablet | |||||
Carvedilol (Non-proprietary) | |||||
celiprolol hydrochloride | Off Formulary | ||||
Vascular Ehlers Danlos Syndrome (vEDS)
On Formulary for vascular Ehlers Danlos Syndrome - approved at July 2021 Drugs and Therapeutics Committee. Starting dose 100mg daily, titrated up to 400mg daily as directed. |
|||||
Oral tablet | |||||
Celiprolol hydrochloride (Non-proprietary) | |||||
Celectol (Neon Healthcare Ltd) | |||||
chlortalidone | On Formulary | ||||
CHLORTALIDONE
Second-line for hypertension as per NICE - Barts Health uses indapamide as first-line choice for a thiazide-like diuretic. |
|||||
Oral tablet | |||||
Chlortalidone (Non-proprietary) | |||||
Hylaton (Morningside Healthcare Ltd) | |||||
clonidine hydrochloride | Hospital Only | ||||
CLONIDINE HYDROCHLORIDE
Not routinely used for headache. |
|||||
February 2024- Clonidine transdermal patches for dystonia in paediatrics (unlicensed)
Clonidine transdermal patches approved at NEL FPG for dystonia in paediatrics (unlicensed). For severe dystonia in patients who could not be adequately managed on oral medications either due to side effects from
Formulary Status: Hospital Only |
|||||
Clonidine tapering of dose
Clonidine is used for agitation in critical care areas. |
|||||
Clonidine for ADHD
Hospital only for ADHD |
|||||
Clonidine Patches 0.1, 0.2 and 0.3mg/day (unlicensed in UK)
Clonidine Patches are for specialist initation only within the hypertension clinic. These are used for the treatment of hypertension where the oral route is inappropriate or there is a lactose allergy to tablets. Doses are initated and titrated within clinic. |
|||||
Oral solution | |||||
Clonidine hydrochloride (Non-proprietary) | |||||
Oral tablet | |||||
Clonidine hydrochloride (Non-proprietary) | |||||
Catapres (Glenwood GmbH) | |||||
co-amilozide | Off Formulary | ||||
Oral tablet | |||||
Co-amilozide (Non-proprietary) | |||||
co-tenidone | Off Formulary | ||||
Oral tablet | |||||
Co-tenidone (Non-proprietary) | |||||
Tenoret (Atnahs Pharma UK Ltd) | |||||
Tenoretic (Atnahs Pharma UK Ltd) | |||||
diltiazem hydrochloride | On Formulary | ||||
DILTIAZEM HYDROCHLORIDE
|
|||||
Modified-release tablet | |||||
Diltiazem hydrochloride (Non-proprietary) | On Formulary | ||||
Retalzem (Kent Pharma (UK) Ltd) | |||||
Tildiem (Sanofi) | |||||
Tildiem Retard (Sanofi) | |||||
Zeyam (Ennogen Pharma Ltd) | |||||
Modified-release capsule | |||||
Adizem-SR (Napp Pharmaceuticals Ltd) | |||||
Adizem-XL (Napp Pharmaceuticals Ltd) | |||||
Angitil SR (Ethypharm UK Ltd) | |||||
Angitil XL (Ethypharm UK Ltd) | |||||
Slozem (Zentiva Pharma UK Ltd) | |||||
Tildiem LA (Sanofi) | |||||
Viazem XL (Thornton & Ross Ltd) | |||||
Zemtard XL (Galen Ltd) | |||||
doxazosin | On Formulary | ||||
DOXAZOSIN
Last line option for hypertension except in renal patients. |
|||||
DOXAZOSIN
|
|||||
Modified-release tablet | |||||
Cardura XL (Viatris UK Healthcare Ltd) | Off Formulary | ||||
Doxadura XL (Dexcel-Pharma Ltd) | Off Formulary | ||||
Larbex XL (Teva UK Ltd) | Off Formulary | ||||
Raporsin XL (Accord-UK Ltd) | Off Formulary | ||||
Oral tablet | |||||
Doxazosin (Non-proprietary) | |||||
Cardura (Viatris UK Healthcare Ltd) | |||||
Doxadura (Dexcel-Pharma Ltd) | |||||
enalapril maleate | On Formulary | ||||
Oral solution | |||||
Enalapril maleate (Non-proprietary) | |||||
Oral tablet | |||||
Enalapril maleate (Non-proprietary) | |||||
Innovace (Organon Pharma (UK) Ltd) | |||||
enalapril with hydrochlorothiazide | Off Formulary | ||||
Oral tablet | |||||
Enalapril with hydrochlorothiazide (Non-proprietary) | |||||
Innozide (Organon Pharma (UK) Ltd) | |||||
eprosartan | Off Formulary | ||||
Oral tablet | |||||
Eprosartan (Non-proprietary) | |||||
Teveten (Viatris UK Healthcare Ltd) | |||||
esmolol hydrochloride | Hospital Only | ||||
Solution for injection | |||||
Esmolol hydrochloride (Non-proprietary) | Hospital Only | ||||
Brevibloc (Baxter Healthcare Ltd) | Hospital Only | ||||
Solution for infusion | |||||
Esmolol hydrochloride (Non-proprietary) | |||||
Brevibloc (Baxter Healthcare Ltd) | |||||
felodipine | On Formulary | ||||
Modified-release tablet | |||||
Cardioplen XL (Chiesi Ltd) | |||||
Delofine XL (Morningside Healthcare Ltd) | |||||
Felendil XL (Teva UK Ltd) | |||||
Felotens XL (Thornton & Ross Ltd) | |||||
Neofel XL (Kent Pharma (UK) Ltd) | |||||
Parmid XL (Sandoz Ltd) | |||||
Pinefeld XL (Tillomed Laboratories Ltd) | |||||
Vascalpha (Accord-UK Ltd) | |||||
fosinopril sodium | Off Formulary | ||||
Oral tablet | |||||
Fosinopril sodium (Non-proprietary) | |||||
furosemide | On Formulary | ||||
FUROSEMIDE
First line for treating fluid accumulation associtated with heart failure.
|
|||||
Oral solution | |||||
Furosemide (Non-proprietary) | On Formulary | ||||
Agreed standard strength for paediatrics
Furosemide 40mg/5ml should be used in adults only 50mg/5ml should be used for all paediatric doses 1mg or greater 20mg/5ml is reserved for Neonatal doses <1mg |
|||||
Frusol (Rosemont Pharmaceuticals Ltd) | |||||
Solution for injection | |||||
Furosemide (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Furosemide (Non-proprietary) | |||||
hydralazine hydrochloride | On Formulary | ||||
HYDRALAZINE HYDROCHLORIDE
IV FORMULATION IS FOR HOSPITAL USE ONLY |
|||||
Powder for solution for injection | |||||
Hydralazine hydrochloride (Non-proprietary) | |||||
Oral tablet | |||||
Hydralazine hydrochloride (Non-proprietary) | |||||
Apresoline (Advanz Pharma) | |||||
hydrochlorothiazide | |||||
imidapril hydrochloride | Off Formulary | ||||
Oral tablet | |||||
Tanatril (Northumbria Pharma Ltd) | |||||
indapamide | On Formulary | ||||
INDAPAMIDE
|
|||||
Modified-release tablet | |||||
Indapamide (Non-proprietary) | |||||
Alkapamid XL (HBS Healthcare Ltd) | |||||
Cardide SR (Teva UK Ltd) | |||||
Lorvacs XL (Torrent Pharma (UK) Ltd) | |||||
Natrilix SR (Servier Laboratories Ltd) | |||||
Oral tablet | |||||
Indapamide (Non-proprietary) | |||||
Natrilix (Servier Laboratories Ltd) | |||||
indoramin | On Formulary | ||||
Oral tablet | |||||
Indoramin (Non-proprietary) | |||||
Doralese Tiltab (Essential Generics Ltd) | |||||
irbesartan | On Formulary | ||||
IRBESARTAN
Renal patients: Hypertension or post MI and heart failure. Heart Failure Guidelines
Secondary prevention of MI Guidelines |
|||||
Oral tablet | |||||
Irbesartan (Non-proprietary) | |||||
Aprovel (Sanofi) | |||||
Ifirmasta (Krka UK Ltd) | |||||
irbesartan with hydrochlorothiazide | |||||
Oral tablet | |||||
Irbesartan with hydrochlorothiazide (Non-proprietary) | |||||
CoAprovel (Sanofi) | |||||
labetalol hydrochloride | On Formulary | ||||
LABETALOL HYDROCHLORIDE
First line for management of hypertension in pregnancy. |
|||||
Solution for injection | |||||
Labetalol hydrochloride (Non-proprietary) | On Formulary | ||||
Labetalol Hydrochloride
Please note: The injection is HOSPITAL ONLY. |
|||||
Oral tablet | |||||
Labetalol hydrochloride (Non-proprietary) | |||||
Trandate (RPH Pharmaceuticals AB) | |||||
lacidipine | On Formulary | ||||
Oral tablet | |||||
Lacidipine (Non-proprietary) | |||||
Molap (Rivopharm (UK) Ltd) | |||||
Motens (GlaxoSmithKline UK Ltd) | |||||
lercanidipine hydrochloride | On Formulary | ||||
Oral tablet | |||||
Lercanidipine hydrochloride (Non-proprietary) | |||||
Zanidip (Recordati Pharmaceuticals Ltd) | |||||
lisinopril | On Formulary | ||||
LISINOPRIL
Heart Failure Guidelines
Secondary prevention of MI Guidelines |
|||||
Oral solution | |||||
Lisinopril (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Lisinopril (Non-proprietary) | |||||
Zestril (Atnahs Pharma UK Ltd) | |||||
lisinopril with hydrochlorothiazide | On Formulary | ||||
Oral tablet | |||||
Lisinopril with hydrochlorothiazide (Non-proprietary) | |||||
Lisoretic (Bristol Laboratories Ltd) | |||||
Zestoretic (Atnahs Pharma UK Ltd) | |||||
losartan potassium | On Formulary | ||||
LOSARTAN POTASSIUM
|
|||||
Oral tablet | |||||
Losartan potassium (Non-proprietary) | |||||
Cozaar (Organon Pharma (UK) Ltd) | |||||
losartan with hydrochlorothiazide | On Formulary | ||||
Oral tablet | |||||
Losartan with hydrochlorothiazide (Non-proprietary) | |||||
Cozaar-Comp (Organon Pharma (UK) Ltd) | |||||
methyldopa | On Formulary | ||||
METHYLDOPA
First line treatment of hypertension in pregancy. |
|||||
Oral tablet | |||||
Methyldopa (Non-proprietary) | |||||
metolazone | Off Formulary | ||||
METOLAZONE
If metolazone available: |
|||||
Switching to the UK licensed preparation of Xaqua®(metolazone) 5mg tablets, May 2023
The Trust switched to the UK licensed preparation of Xaqua®(metolazone) 5mg tablets for all areas across the Trust. |
|||||
Metolazone caution with loop diuretics
Metolazone is a potent diuretic and when used with loop diuretics can cause a dramatic diuresis and disturbance to fluid balance and electrolytes due to sequential blockade of the nephron. Patients must be closely monitored and this combination should only be initiated by specialists with experience of using this combination e.g. cardiology or renal teams. Any patient discharged on the combination should have an outpatient follow-up appointment within two weeks. NOTE: Unlicensed |
|||||
Oral tablet | |||||
Metolazone (Non-proprietary) | |||||
Xaqua (Renascience Pharma Ltd) | |||||
metoprolol tartrate | On Formulary | ||||
METOPROLOL TARTRATE
Initiation for atrial fibrillation, hypertension, secondary prevention of MI, heart failure, stable angina. https://www.nice.org.uk/guidance/ng185 https://www.nice.org.uk/guidance/ng196 https://www.nice.org.uk/guidance/ng133 https://www.nice.org.uk/guidance/cg126
|
|||||
Solution for injection | |||||
Betaloc (Recordati Pharmaceuticals Ltd) | Hospital Only | ||||
Oral tablet | |||||
Metoprolol tartrate (Non-proprietary) | |||||
minoxidil | On Formulary | ||||
Cutaneous solution | |||||
Regaine (Johnson & Johnson Ltd, McNeil Products Ltd) | |||||
Cutaneous foam | |||||
Regaine (McNeil Products Ltd) | |||||
Regaine for Women Once a Day (McNeil Products Ltd) | |||||
Oral tablet | |||||
Minoxidil (Non-proprietary) | |||||
Loniten (Pfizer Ltd) | |||||
moxonidine | On Formulary | ||||
MOXONIDINE
For hypertension. |
|||||
Oral tablet | |||||
Moxonidine (Non-proprietary) | |||||
Physiotens (Viatris UK Healthcare Ltd) | |||||
nadolol | Off Formulary | ||||
Oral tablet | |||||
Nadolol (Non-proprietary) | |||||
nebivolol | On Formulary | ||||
NEBIVOLOL
Specialist initiation with PEFR monitoring in hospital. (NB: mild to moderate COPD is not a contraindication for use of other cardioselective beta blockers) |
|||||
Oral tablet | |||||
Nebivolol (Non-proprietary) | |||||
Nebilet (A. Menarini Farmaceutica Internazionale SRL) | |||||
nicardipine hydrochloride | On Formulary | ||||
Solution for infusion | |||||
Nicardipine hydrochloride (Non-proprietary) | Hospital Only | ||||
Oral capsule | |||||
Cardene (Laboratoire X.O) | |||||
nifedipine | On Formulary | ||||
Leiomyoma pain
Nidfedipine 10-20mg daily or twice daily is used in dermatology for pain resulting from leiomyoma |
|||||
Modified-release tablet | |||||
Adalat LA (Bayer Plc) | On Formulary | ||||
Leiomyoma pain
Nidfedipine 10-20mg daily or twice daily is used in dermatology for pain resulting from leiomyoma |
|||||
Adanif XL (Advanz Pharma) | |||||
Adipine MR (Chiesi Ltd) | |||||
Adipine XL (Chiesi Ltd) | |||||
Dexipress MR (Dexcel-Pharma Ltd) | |||||
Fortipine LA (Advanz Pharma) | |||||
Neozipine XL (Kent Pharma (UK) Ltd) | |||||
Nifedipress MR (Dexcel-Pharma Ltd) | |||||
Tensipine MR (Genus Pharmaceuticals Ltd) | |||||
Valni Retard (Tillomed Laboratories Ltd) | |||||
Modified-release capsule | |||||
Coracten SR (Teofarma S.r.l.) | |||||
Coracten XL (Teofarma S.r.l.) | |||||
Oral drops | |||||
Nifedipine (Non-proprietary) | |||||
Oral capsule | |||||
Nifedipine (Non-proprietary) | |||||
olmesartan medoxomil | Off Formulary | ||||
Oral tablet | |||||
Olmesartan medoxomil (Non-proprietary) | |||||
Olmetec (Daiichi Sankyo UK Ltd) | |||||
olmesartan with amlodipine | Off Formulary | ||||
Oral tablet | |||||
Sevikar (Daiichi Sankyo UK Ltd) | |||||
olmesartan with amlodipine and hydrochlorothiazide | On Formulary | ||||
Oral tablet | |||||
Sevikar HCT (Daiichi Sankyo UK Ltd) | |||||
olmesartan with hydrochlorothiazide | Off Formulary | ||||
Oral tablet | |||||
Olmesartan with hydrochlorothiazide (Non-proprietary) | |||||
Olmetec Plus (Daiichi Sankyo UK Ltd) | |||||
perindopril arginine | Off Formulary | ||||
Oral tablet | |||||
Coversyl Arginine (Servier Laboratories Ltd) | |||||
perindopril arginine with indapamide | |||||
Oral tablet | |||||
Coversyl Arginine Plus (Servier Laboratories Ltd) | |||||
perindopril erbumine | On Formulary | ||||
PERINDOPRIL ERBUMINE
Heart Failure Guidelines
|
|||||
Oral tablet | |||||
Perindopril erbumine (Non-proprietary) | |||||
perindopril erbumine with amlodipine | |||||
pindolol | Off Formulary | ||||
prazosin | Off Formulary | ||||
Oral tablet | |||||
Prazosin (Non-proprietary) | |||||
Hypovase (Pfizer Ltd) | |||||
propranolol hydrochloride | On Formulary | ||||
PROPRANOLOL HYDROCHLORIDE
Phaechromocytoma (usually started 24 hours after Phenoxybenzamine) |
|||||
PROPRANOLOL for thyrotoxicosis
Symptomatic relief of thyrotoxicosis- |
|||||
Modified-release capsule | |||||
Bedranol SR (Almus Pharmaceuticals Ltd, Sandoz Ltd) | |||||
Propranolol
Whipps Cross: somatic manifestations of acute alcohol withdrawal- see alcohol dependance for more information |
|||||
Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Half Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Oral solution | |||||
Propranolol hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Propranolol hydrochloride (Non-proprietary) | |||||
quinapril | Off Formulary | ||||
Oral tablet | |||||
Quinapril (Non-proprietary) | |||||
Accupro (Pfizer Ltd) | |||||
quinapril with hydrochlorothiazide | Off Formulary | ||||
Oral tablet | |||||
Accuretic (Pfizer Ltd) | |||||
ramipril | On Formulary | ||||
RAMIPRIL
First-line ACEI for hypertension, heart failure, secondary prevention of MI. https://www.nice.org.uk/guidance/ng106 |
|||||
Oral solution | |||||
Ramipril (Non-proprietary) | On Formulary | ||||
RAMIPRIL
First-line ACEI for hypertension, heart failure, secondary prevention of MI. |
|||||
Oral tablet | |||||
Ramipril (Non-proprietary) | |||||
Tritace (Sanofi) | |||||
Oral capsule | |||||
Ramipril (Non-proprietary) | |||||
ramipril with felodipine | Off Formulary | ||||
spironolactone | On Formulary | ||||
SPIRONOLACTONE
Hypertension: Consider further diuretic therapy with low-dose spironolactone (25 mg once daily) if the blood potassium level is 4.5 mmol/l or lower. Use particular caution in people with a reduced estimated glomerular filtration rate because they have an increased risk of hyperkalaemia. NICE CG 127 |
|||||
Oral solution | |||||
Spironolactone (Non-proprietary) | |||||
Oral tablet | |||||
Spironolactone (Non-proprietary) | |||||
Aldactone (Pfizer Ltd) | |||||
telmisartan | Off Formulary | ||||
Oral tablet | |||||
Telmisartan (Non-proprietary) | |||||
Micardis (Boehringer Ingelheim Ltd) | |||||
telmisartan with hydrochlorothiazide | Off Formulary | ||||
Oral tablet | |||||
Telmisartan with hydrochlorothiazide (Non-proprietary) | |||||
MicardisPlus (Boehringer Ingelheim Ltd) | |||||
MicardisPlus 80/25 (Boehringer Ingelheim Ltd) | |||||
Tolucombi (Krka UK Ltd) | |||||
terazosin | Off Formulary | ||||
Form unstated | |||||
Hytrin (Advanz Pharma) | |||||
Oral tablet | |||||
Terazosin (Non-proprietary) | |||||
Hytrin (Advanz Pharma) | |||||
timolol maleate | Off Formulary | ||||
Eye drops | |||||
Timolol maleate (Non-proprietary) | |||||
Eysano (Aspire Pharma Ltd) | |||||
Timoptol (Santen UK Ltd) | |||||
Tiopex (Thea Pharmaceuticals Ltd) | |||||
Once-daily preparations
Long acting preparations of timolol are used in dermatology for cutaneous haemangioma |
|||||
Eye gel | |||||
Timoptol-LA (Santen UK Ltd) | |||||
Oral tablet | |||||
Timolol maleate (Non-proprietary) | |||||
timolol with bendroflumethiazide | Off Formulary | ||||
Oral tablet | |||||
Timolol with bendroflumethiazide (Non-proprietary) | |||||
torasemide | Off Formulary | ||||
Oral tablet | |||||
Torasemide (Non-proprietary) | |||||
Torem (Viatris UK Healthcare Ltd) | |||||
trandolapril | Off Formulary | ||||
Oral capsule | |||||
Trandolapril (Non-proprietary) | |||||
triamterene with chlortalidone | Off Formulary | ||||
Oral tablet | |||||
Triamterene with chlortalidone (Non-proprietary) | |||||
valsartan | On Formulary | ||||
VALSARTAN
Last-line option post-MI Heart Failure Guidelines
https://www.nice.org.uk/guidance/ng106 Hypertension Guidelines https://pathways.nice.org.uk/pathways/hypertension Secondary prevention of MI Guidelines |
|||||
Oral solution | |||||
Diovan (Novartis Pharmaceuticals UK Ltd) | |||||
Oral tablet | |||||
Valsartan (Non-proprietary) | |||||
Oral capsule | |||||
Valsartan (Non-proprietary) | |||||
valsartan with hydrochlorothiazide | Off Formulary | ||||
Oral tablet | |||||
Valsartan with hydrochlorothiazide (Non-proprietary) | |||||
Co-Diovan (Novartis Pharmaceuticals UK Ltd) | |||||
verapamil hydrochloride | On Formulary | ||||
VERAPAMIL HYDROCHLORIDE
For rate controlled angina. https://www.nice.org.uk/guidance/ng196 Stable angina |
|||||
Modified-release tablet | |||||
Half Securon (Viatris UK Healthcare Ltd) | On Formulary | ||||
Securon SR (Viatris UK Healthcare Ltd) | On Formulary | ||||
Vera-Til SR (Accord-UK Ltd, Tillomed Laboratories Ltd) | On Formulary | ||||
Verapress MR (Dexcel-Pharma Ltd) | On Formulary | ||||
Oral solution | |||||
Verapamil hydrochloride (Non-proprietary) | On Formulary | ||||
Solution for injection | |||||
Securon (Viatris UK Healthcare Ltd) | Hospital Only | ||||
Oral tablet | |||||
Verapamil hydrochloride (Non-proprietary) | |||||
xipamide | Off Formulary | ||||
Oral tablet | |||||
Diurexan (Viatris UK Healthcare Ltd) | |||||
Cardiovascular system / Portal hypertension | |||||
carvedilol | |||||
Oral tablet | |||||
Carvedilol (Non-proprietary) | |||||
propranolol hydrochloride | On Formulary | ||||
PROPRANOLOL HYDROCHLORIDE
Phaechromocytoma (usually started 24 hours after Phenoxybenzamine) |
|||||
PROPRANOLOL for thyrotoxicosis
Symptomatic relief of thyrotoxicosis- |
|||||
Modified-release capsule | |||||
Bedranol SR (Almus Pharmaceuticals Ltd, Sandoz Ltd) | |||||
Propranolol
Whipps Cross: somatic manifestations of acute alcohol withdrawal- see alcohol dependance for more information |
|||||
Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Half Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Oral solution | |||||
Propranolol hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Propranolol hydrochloride (Non-proprietary) | |||||
Cardiovascular system / Pulmonary hypertension | |||||
ambrisentan | Off Formulary | ||||
AMBRISENTAN
HOSPITAL ONLY |
|||||
Oral tablet | |||||
Ambrisentan (Non-proprietary) | |||||
Volibris (GlaxoSmithKline UK Ltd) | |||||
bosentan | Off Formulary | ||||
BOSENTAN
HOSPITAL ONLY |
|||||
Oral tablet | |||||
Bosentan (Non-proprietary) | |||||
epoprostenol | Hospital Only | ||||
Nebulised Epoprostenol in Critical Care
Can be nebulised for ventilated patients with hypoxaemia in context acute respiratory distress syndrome and/or raised pulmonary vascular resistance within intensive care setting - refer to local guideline - note this is unlicensed use |
|||||
Epoprostenol PVD
Indication Initial Dose Treatment Duration Peripheral Vascular Disease 2nanograms/kg/min increased by 1 nanogram/kg/min up to 10nanograms/kg/min or until limited by side effects. The average dose is 5 – 7 nanograms/kg/min. Treatment is for 72 hours continuously. Raynaud’s Phenomenon 2nanograms/kg/min increased by 1 nanogram/kg/min up to 10nanograms/kg/min or until limited by side effects Treatment is for 12 hours daily and is usually repeated for 3 – 5 consecutive days
Intervals increased at increments of at least 15 minutes
|
|||||
Blocked catheters and lines - in renal dialysis
Blocked catheters and lines - note, this relates to those on renal dialysis - further details below in indications |
|||||
Powder for solution for infusion | |||||
Epoprostenol (Non-proprietary) | |||||
Veletri (Janssen-Cilag Ltd) | |||||
Powder and solvent for solution for infusion | |||||
Flolan (GlaxoSmithKline UK Ltd) | |||||
Epoprostenol PVD
Indication Initial Dose Treatment Duration Peripheral Vascular Disease 2nanograms/kg/min increased by 1 nanogram/kg/min up to 10nanograms/kg/min or until limited by side effects. The average dose is 5 – 7 nanograms/kg/min. Treatment is for 72 hours continuously. Raynaud’s Phenomenon 2nanograms/kg/min increased by 1 nanogram/kg/min up to 10nanograms/kg/min or until limited by side effects Treatment is for 12 hours daily and is usually repeated for 3 – 5 consecutive days. Intervals increased at increments of at least15 minutes |
|||||
iloprost | Hospital Only | ||||
ILOPROST
FOR HOSPITAL USE ONLY |
|||||
Solution for infusion | |||||
Iloprost (Non-proprietary) | |||||
Nebuliser liquid | |||||
Iloprost (Non-proprietary) | |||||
Ventavis (Bayer Plc) | |||||
macitentan | Off Formulary | ||||
Oral tablet | |||||
Opsumit (Janssen-Cilag Ltd) | |||||
riociguat | Off Formulary | ||||
Oral tablet | |||||
Adempas (Merck Sharp & Dohme (UK) Ltd) | |||||
selexipag | Off Formulary | ||||
Oral tablet | |||||
Uptravi (Janssen-Cilag Ltd) | |||||
sildenafil | Hospital Only | ||||
Oral suspension | |||||
Sildenafil (Non-proprietary) | |||||
Revatio (Viatris UK Healthcare Ltd) | |||||
Solution for injection | |||||
Revatio (Viatris UK Healthcare Ltd) | |||||
Oral tablet | |||||
Sildenafil (Non-proprietary) | |||||
Granpidam (Accord-UK Ltd) | |||||
Revatio (Viatris UK Healthcare Ltd) | |||||
Viagra (Viatris UK Healthcare Ltd) | |||||
tadalafil | Off Formulary | ||||
Oral tablet | |||||
Tadalafil (Non-proprietary) | |||||
Adcirca (Eli Lilly and Company Ltd) | |||||
Cialis (Eli Lilly and Company Ltd) | |||||
Talmanco (Viatris UK Healthcare Ltd) | |||||
treprostinil | |||||
Solution for infusion | |||||
Treprostinil (Non-proprietary) | |||||
Treposuvi (AOP Orphan Ltd) | |||||
Trepulmix (AOP Orphan Ltd) | |||||
Cardiovascular system / Hypertension associated with phaeochromocytoma | |||||
phenoxybenzamine hydrochloride | Hospital Only | ||||
PHENOXYBENZAMINE HYDROCHLORIDE
INJECTION FORMULATION IS FOR HOSPITAL USE ONLY
NOTE - long term manufacturing issues - not currently available |
|||||
Oral capsule | |||||
Phenoxybenzamine hydrochloride (Non-proprietary) | |||||
propranolol hydrochloride | On Formulary | ||||
PROPRANOLOL HYDROCHLORIDE
Phaechromocytoma (usually started 24 hours after Phenoxybenzamine) |
|||||
PROPRANOLOL for thyrotoxicosis
Symptomatic relief of thyrotoxicosis- |
|||||
Modified-release capsule | |||||
Bedranol SR (Almus Pharmaceuticals Ltd, Sandoz Ltd) | |||||
Propranolol
Whipps Cross: somatic manifestations of acute alcohol withdrawal- see alcohol dependance for more information |
|||||
Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Half Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Oral solution | |||||
Propranolol hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Propranolol hydrochloride (Non-proprietary) | |||||
Cardiovascular system / Hypertensive crises | |||||
hydralazine hydrochloride | On Formulary | ||||
HYDRALAZINE HYDROCHLORIDE
IV FORMULATION IS FOR HOSPITAL USE ONLY |
|||||
Powder for solution for injection | |||||
Hydralazine hydrochloride (Non-proprietary) | On Formulary | ||||
HYDRALAZINE HYDROCHLORIDE
IV FORMULATION IS FOR HOSPITAL USE ONLY |
|||||
Oral tablet | |||||
Hydralazine hydrochloride (Non-proprietary) | |||||
Apresoline (Advanz Pharma) | |||||
labetalol hydrochloride | On Formulary | ||||
LABETALOL HYDROCHLORIDE
First line for management of hypertension in pregnancy. |
|||||
Solution for injection | |||||
Labetalol hydrochloride (Non-proprietary) | On Formulary | ||||
Labetalol Hydrochloride
Please note: The injection is HOSPITAL ONLY. |
|||||
Oral tablet | |||||
Labetalol hydrochloride (Non-proprietary) | |||||
Trandate (RPH Pharmaceuticals AB) | |||||
sodium nitroprusside | Hospital Only | ||||
Powder and solvent for solution for infusion | |||||
Sodium nitroprusside (Non-proprietary) | |||||
Cardiovascular system / Hypotension and shock | |||||
Etilefrine | On Formulary | ||||
Etilefrine for priapism
Etilefrine 25mg tablets available as named patient for priapism. |
|||||
Etilefrine
Approved Indication at Barts Health |
|||||
angiotensin II | |||||
Solution for infusion | |||||
Giapreza (PAION Deutschland GmbH) | |||||
dobutamine | Hospital Only | ||||
Solution for infusion | |||||
Dobutamine (Non-proprietary) | On Formulary | ||||
dopamine hydrochloride | Hospital Only | ||||
Solution for infusion | |||||
Dopamine hydrochloride (Non-proprietary) | On Formulary | ||||
ephedrine hydrochloride | Hospital Only | ||||
Inhaled Ephedrine (Primatene Mist)- Non-formulary
Inhaled Ephedrine is not recommended for the treatment of asthma. Please contact the Pharmacy respiratory team for advice if ever prescribed for asthma. Please contact Emergency Medicine Lead Pharmacist for advice if prescribed for patient in ED. |
|||||
Solution for injection | |||||
Ephedrine hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Ephedrine hydrochloride (Non-proprietary) | |||||
metaraminol | Hospital Only | ||||
Metaraminol 2.5mg/5ml ampoules shortage
This shortage will primarily affect the Newham University Hospital and Whipps Cross University Hospital sites and is likely to last until the end of December 2020.
See attached memo |
|||||
Metaraminol - ICU recovery protocol
see attached |
|||||
Solution for injection | |||||
Metaraminol (Non-proprietary) | On Formulary | ||||
Metaraminol - ICU recovery protocol
see attached |
|||||
midodrine hydrochloride | On Formulary | ||||
Midodrine for orthostatic hypotension or vasovagal syncope
Midodrine |
|||||
Oral tablet | |||||
Midodrine hydrochloride (Non-proprietary) | |||||
Bramox (Brancaster Pharma Ltd) | |||||
noradrenaline/norepinephrine | Hospital Only | ||||
Noradrenaline IV Monograph (Adult Critical Care Only)
For use in Adult Critical Care areas only. |
|||||
Solution for infusion | |||||
Noradrenaline/norepinephrine (Non-proprietary) | On Formulary | ||||
Sinora (Sandoz Ltd) | |||||
phenylephrine hydrochloride | On Formulary | ||||
Solution for injection | |||||
Phenylephrine hydrochloride (Non-proprietary) | On Formulary | ||||
Eye drops | |||||
Phenylephrine hydrochloride (Non-proprietary) | |||||
sodium nitroprusside | Hospital Only | ||||
Powder and solvent for solution for infusion | |||||
Sodium nitroprusside (Non-proprietary) | |||||
Cardiovascular system / Vascular disease | |||||
cilostazol | Off Formulary |
NICE TA223 |
|||
Oral tablet | |||||
Cilostazol (Non-proprietary) | |||||
iloprost | |||||
Solution for infusion | |||||
Iloprost (Non-proprietary) | |||||
Nebuliser liquid | |||||
Iloprost (Non-proprietary) | |||||
Ventavis (Bayer Plc) | |||||
inositol nicotinate | Off Formulary |
NICE TA223 |
|||
Oral capsule | |||||
Inositol nicotinate (Non-proprietary) | |||||
naftidrofuryl oxalate | On Formulary |
NICE TA223 |
|||
NAFTIDROFURYL OXALATE
First-line option for peripheral arterial disease. |
|||||
Oral capsule | |||||
Naftidrofuryl oxalate (Non-proprietary) | |||||
Praxilene (Merck Serono Ltd) | |||||
nifedipine | On Formulary | ||||
Leiomyoma pain
Nidfedipine 10-20mg daily or twice daily is used in dermatology for pain resulting from leiomyoma |
|||||
Modified-release tablet | |||||
Adalat LA (Bayer Plc) | On Formulary | ||||
Leiomyoma pain
Nidfedipine 10-20mg daily or twice daily is used in dermatology for pain resulting from leiomyoma |
|||||
Adanif XL (Advanz Pharma) | |||||
Adipine MR (Chiesi Ltd) | |||||
Adipine XL (Chiesi Ltd) | |||||
Dexipress MR (Dexcel-Pharma Ltd) | |||||
Fortipine LA (Advanz Pharma) | |||||
Neozipine XL (Kent Pharma (UK) Ltd) | |||||
Nifedipress MR (Dexcel-Pharma Ltd) | |||||
Tensipine MR (Genus Pharmaceuticals Ltd) | |||||
Valni Retard (Tillomed Laboratories Ltd) | |||||
Modified-release capsule | |||||
Coracten SR (Teofarma S.r.l.) | |||||
Coracten XL (Teofarma S.r.l.) | |||||
Oral drops | |||||
Nifedipine (Non-proprietary) | |||||
Oral capsule | |||||
Nifedipine (Non-proprietary) | |||||
oxerutins | Off Formulary | ||||
Oral capsule | |||||
Paroven (Thornton & Ross Ltd) | |||||
pentoxifylline | On Formulary |
NICE TA223 |
|||
Modified-release tablet | |||||
Trental (Neuraxpharm UK Ltd) | |||||
prazosin | Off Formulary | ||||
Oral tablet | |||||
Prazosin (Non-proprietary) | |||||
Hypovase (Pfizer Ltd) | |||||
Cardiovascular system / Vein malformations | |||||
lauromacrogol 400 | |||||
Solution for injection | |||||
Lauromacrogol 400 (Non-proprietary) | |||||
Aethoxysklerol (Kora Healthcare) | |||||
sodium tetradecyl sulfate | On Formulary | ||||
SODIUM TETRADECYL SULFATE
Sclerotherapy of varicose veins. |
|||||
Solution for injection | |||||
Fibro-Vein (STD Pharmaceutical Products Ltd) | On Formulary | ||||
Cardiovascular system / Cardiomyopathy | |||||
mavacamten | Hospital Only |
NICE TA913 |
|||
NICE TA 913 - December 2023 - Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten approved at NEL FPG for treating symptomatic obstructive hypertrophic cardiomyopathy in line with NICE TA
**Patient must have explicit counselling with respect to patient specific interactions.
Hospital Only
|
|||||
Oral capsule | |||||
Camzyos (Bristol-Myers Squibb Pharmaceuticals Ltd) | |||||
Cardiovascular system / Cardiac diagnostic procedures and surgeries | |||||
Custodial® HTK Solution | Hospital Only | ||||
Perflutren (Luminity®) | Hospital Only | ||||
dobutamine | Hospital Only | ||||
Solution for infusion | |||||
Dobutamine (Non-proprietary) | On Formulary | ||||
Cardiovascular system / Blocked catheters and lines | |||||
epoprostenol | Hospital Only | ||||
Nebulised Epoprostenol in Critical Care
Can be nebulised for ventilated patients with hypoxaemia in context acute respiratory distress syndrome and/or raised pulmonary vascular resistance within intensive care setting - refer to local guideline - note this is unlicensed use |
|||||
Blocked catheters and lines - in renal dialysis
Blocked catheters and lines - note, this relates to those on renal dialysis - further details below in indications |
|||||
Powder for solution for infusion | |||||
Epoprostenol (Non-proprietary) | |||||
Veletri (Janssen-Cilag Ltd) | |||||
Powder and solvent for solution for infusion | |||||
Flolan (GlaxoSmithKline UK Ltd) | |||||
heparin (unfractionated) | On Formulary | ||||
Unfractionated Heparin (UFH): Monitoring in Adult Patients
See below |
|||||
Solution for injection | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: |
|||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: |
|||||
Guidelines for the Diagnosis, Investigation and Management of
Heparin-Induced Thrombocytopenia (HIT)
Guidelines for the Diagnosis, Investigation and Management of
Heparin-Induced Thrombocytopenia (HIT)
HIT Guidelines 2016 |
|||||
Infusion | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: Weight Rate(2) - mls per hourof 1000units in 1ml concentration Greater than 90kg 1.7 81-90kg 1.6 71-80kg 1.4 61-70kg 1.2 51-60kg 1.0 41-50kg 0.8 |
|||||
Form unstated | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
urokinase | On Formulary | ||||
UROKINASE
Unblocking catheters: |
|||||
Powder for solution for injection | |||||
Syner-KINASE (Syner-Med (Pharmaceutical Products) Ltd) | |||||
Cardiovascular system / Thromboembolism | |||||
acenocoumarol | On Formulary | ||||
Oral tablet | |||||
Sinthrome (Norgine Pharmaceuticals Ltd) | |||||
alteplase | Hospital Only |
NICE TA264 |
|||
PE guidelines
See below for link to guidelines |
|||||
ALTEPLASE
For treatment of stroke and PE |
|||||
Thrombolysis with Alteplase
. |
|||||
Powder and solvent for solution for injection | |||||
Actilyse (Boehringer Ingelheim Ltd) | Hospital Only | ||||
Powder and solvent for solution for infusion | |||||
Actilyse (Boehringer Ingelheim Ltd) | Hospital Only | ||||
andexanet alfa | Hospital Only |
NICE TA697 |
|||
Reversing anticoagulation from apixaban or rivaroxaban
Approved by DTC as per NICE TA 697 |
|||||
Powder for solution for infusion | |||||
Ondexxya (AstraZeneca UK Ltd) | |||||
apixaban | On Formulary |
NICE TA245 NICE TA275 NICE TA341 |
|||
Anticoagulation intranet page
Scroll down for links to documents on the fileshare |
|||||
Selection of NOAC guidance
see attached |
|||||
Apixaban: Primary Care Prescriber Information
Apixaban: Primary Care Prescriber Information |
|||||
APIXABAN (other uses)
|
|||||
Transfer of Care document - Treatment of PE in COVID patients
see attached |
|||||
May-2024, Apixaban- Following gynecology oncology surgery (off-label)
Apixaban approved at NEL FPG for prophylaxis of venous thromboembolism (VTE) following gynaecology oncology surgery at Barts Health NHS Trust.
Formulary Status: Hospital Only |
|||||
GUIDELINES/COUNSELLING CHECKLIST
See below for link to guidelines and counselling checklist: |
|||||
Oral tablet | |||||
Apixaban (Non-proprietary) | |||||
Eliquis (Bristol-Myers Squibb Pharmaceuticals Ltd) | |||||
argatroban monohydrate | Hospital Only | ||||
Heparin Induced Thrombocytopenia (HIT)
https://weshare.bartshealth.nhs.uk/haematology-immunology?media_item=16727&media_type=10#file-viewer |
|||||
Solution for infusion | |||||
Argatroban monohydrate (Non-proprietary) | |||||
Exembol (Mitsubishi Tanabe Pharma Europe Ltd) | |||||
aspirin | On Formulary | ||||
Aspirin
Should not routinely used for primary prevention of cardiovascular disease.
Aspirin has multiple indications, follow the links below for more information
|
|||||
Dispersible tablet | |||||
Aspirin (Non-proprietary) | |||||
Disprin (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Gastro-resistant tablet | |||||
Aspirin (Non-proprietary) | |||||
Nu-Seals (Alliance Pharmaceuticals Ltd) | |||||
Suppository | |||||
Aspirin (Non-proprietary) | |||||
Oral tablet | |||||
Aspirin (Non-proprietary) | |||||
bemiparin sodium | |||||
bivalirudin | Hospital Only | ||||
Heparin Induced Thrombocytopenia (HIT)
https://weshare.bartshealth.nhs.uk/haematology-immunology?media_item=16727&media_type=10#file-viewer |
|||||
Powder for solution for infusion | |||||
Bivalirudin (Non-proprietary) | |||||
clopidogrel | On Formulary |
NICE TA210 |
|||
Antiplatelet and eptifibatide advice in Acute Coronary Syndromes
|
|||||
CLOPIDOGREL
First-line monotherapy after acute phase for ischaemic stroke in absence of atrial fibrillation. Assess bleeding risk for co-prescription of PPIs. Commonly loaded with 600mg prior to coronary artery stenting (with or with out ACS) - NOTE this is an unlicensed dose Consider lansoprazole or H2 antagonists (ranitidine) as gastroprotection with clopidogrel treatment. |
|||||
Oral tablet | |||||
Clopidogrel (Non-proprietary) | |||||
Plavix (Sanofi) | |||||
dabigatran etexilate | On Formulary |
NICE TA157 NICE TA249 NICE TA327 |
|||
GUIDELINES/COUNSELLING CHECKLIST
See below for links to guidelines and counselling checklist |
|||||
Dabigatran reversal agent: Idarucizumab
Is a specific reversal agent for dabigatran - used for when rapid reversal of anticoagulation is required
The dose is the same for all patients: 5g (2 X 2.5g) administered intravenously as two consecutive infusions of 2.5g/50mL each time. |
|||||
Primary Care Prescriber Information
Dabigatran: Primary Care Prescriber Information |
|||||
DABIGATRAN ETEXILATE (other uses)
|
|||||
Anticoagulation Contacts
Scroll down for links to documents on the fileshare |
|||||
Oral capsule | |||||
Dabigatran etexilate (Non-proprietary) | |||||
Pradaxa (Boehringer Ingelheim Ltd) | |||||
dalteparin sodium | Off Formulary | ||||
Solution for injection | |||||
Fragmin (Pfizer Ltd) | |||||
danaparoid sodium | On Formulary | ||||
Solution for injection | |||||
Danaparoid sodium (Non-proprietary) | On Formulary | ||||
dipyridamole | On Formulary |
NICE TA210 |
|||
DIPYRIDAMOLE
|
|||||
Modified-release capsule | |||||
Dipyridamole (Non-proprietary) | |||||
Attia (Dr Reddy's Laboratories (UK) Ltd) | |||||
Oral suspension | |||||
Dipyridamole (Non-proprietary) | |||||
Oral tablet | |||||
Dipyridamole (Non-proprietary) | |||||
edoxaban | On Formulary |
NICE TA354 NICE TA355 |
|||
GUIDELINES/COUNSELLING CHECKLIST
See links below for guidelines and counselling checklist |
|||||
Edoxaban: Primary Care Prescriber Information
Edoxaban: Primary Care Prescriber Information |
|||||
Edoxaban (other uses)
|
|||||
Anticoagulation intranet page
Scroll down for links to documents on the fileshare |
|||||
Oral tablet | |||||
Lixiana (Daiichi Sankyo UK Ltd) | |||||
enoxaparin sodium | On Formulary | ||||
LMWH Shared Care Guideline
LMWH Shared Care Guideline |
|||||
GUIDELINES
See below for links to guidelines |
|||||
Transfer of Care document - Treatment of PE in COVID patients
see attached |
|||||
Peri-operative management
Peri-operative management |
|||||
Anticoagulation Contacts
Scroll down for links to documents on the fileshare |
|||||
Solution for injection | |||||
Arovi (ROVI Biotech Ltd) | |||||
Clexane (Sanofi) | On Formulary | ||||
Anticoagulation intranet page
Scroll down for links to documents on the fileshare |
|||||
Enoxaparin shared care guidelines
|
|||||
Inhixa (Techdow Pharma England Ltd) | |||||
Ledraxen (Tetris Pharma Ltd) | |||||
fondaparinux sodium | On Formulary | ||||
Fondaparinux in acute coronary syndrome
Fondaparinux is now the trusts formulary choice of anticoagulant in NSTEMI-ACS. Dose 2.5mg ONCE DAILY Mode of administration Subcutaneous If undergoing PCI Preferably undergo PCI 4 - 24 hours after receiving the last fondaparinux dose and use UFH as an adjunct as per current practice. USE ALTERNATIVE anticoagulant if patient has a pre existing medical condition requiring anticoagulation - i.e. AF, DVT, mechanical valve etc - use enoxaparin 1mg/kg twice daily (adjusted for renal function). To stop post angioplasty unless clinically indicated Platelet monitoring Not required Contra-indication CrCl <20mls/mins if known, and use UFH |
|||||
FONDAPARINUX SODIUM
For acute coronary syndrome |
|||||
Heparin Induced Thrombocytopenia (HIT)
https://weshare.bartshealth.nhs.uk/haematology-immunology?media_item=16727&media_type=10#file-viewer |
|||||
Solution for injection | |||||
Fondaparinux sodium (Non-proprietary) | On Formulary | ||||
Fondaparinux in acute coronary syndrome
Fondaparinux is now the trusts formulary choice of anticoagulant in NSTEMI-ACS. Dose 2.5mg ONCE DAILY Mode of administration Subcutaneous If undergoing PCI Preferably undergo PCI 4 - 24 hours after receiving the last fondaparinux dose and use UFH as an adjunct as per current practice. To stop post angioplasty unless clinically indicated Platelet monitoring Not required Contra-indication CrCl <20mls/mins if known, and use UFH |
|||||
Arixtra (Viatris UK Healthcare Ltd) | On Formulary | ||||
Fondaparinux in acute coronary syndrome
Fondaparinux is now the trusts formulary choice of anticoagulant in NSTEMI-ACS. Dose 2.5mg ONCE DAILY Mode of administration Subcutaneous If undergoing PCI Preferably undergo PCI 4 - 24 hours after receiving the last fondaparinux dose and use UFH as an adjunct as per current practice. To stop post angioplasty unless clinically indicated Platelet monitoring Not required Contra-indication CrCl <20mls/mins if known, and use UFH |
|||||
heparin (unfractionated) | On Formulary | ||||
Unfractionated Heparin (UFH): Monitoring in Adult Patients
See below |
|||||
Solution for injection | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: |
|||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: |
|||||
Guidelines for the Diagnosis, Investigation and Management of
Heparin-Induced Thrombocytopenia (HIT)
Guidelines for the Diagnosis, Investigation and Management of
Heparin-Induced Thrombocytopenia (HIT)
HIT Guidelines 2016 |
|||||
Infusion | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: Weight Rate(2) - mls per hourof 1000units in 1ml concentration Greater than 90kg 1.7 81-90kg 1.6 71-80kg 1.4 61-70kg 1.2 51-60kg 1.0 41-50kg 0.8 |
|||||
Form unstated | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
idarucizumab | Hospital Only | ||||
Idarucizumab
Is a specific reversal agent for dabigatran - used for when rapid reversal of anticoagulation is required
The dose is the same for all patients: 5g (2 X 2.5g) administered intravenously as two consecutive infusions of 2.5g/50mL each time. |
|||||
Stock control of Idarucizumab
across Barts Health NHS Trust
see attached |
|||||
Guidelines for management of bleeding with NOACs - 2016
see attached |
|||||
Solution for infusion | |||||
Praxbind (Boehringer Ingelheim Ltd) | |||||
phenindione | Off Formulary | ||||
Oral tablet | |||||
Phenindione (Non-proprietary) | |||||
prasugrel | On Formulary |
NICE TA317 |
|||
PRASUGREL
Specialist initiation for acute coronary syndrome - third line after other P2Y12 inhibitors not tolerated or unable to be used due to interactions.
|
|||||
Approved for neurovascular stenting for patients who are resistant to clopidogrel
Approved September DTC 2021 |
|||||
Oral tablet | |||||
Prasugrel (Non-proprietary) | |||||
Efient (Vygoris Ltd) | |||||
rivaroxaban | On Formulary |
NICE TA170 NICE TA256 NICE TA261 NICE TA287 NICE TA335 NICE TA607 |
|||
GUIDELINES/COUNSELLING CHECKLIST
See below for links to guidelines and counselling checklist |
|||||
Rivaroxaban: Primary Care Prescriber Information
Rivaroxaban: Primary Care Prescriber Information |
|||||
Heparin Induced Thrombocytopenia (HIT) approved October 2020 DTC
On formulary for Heparin Induced Thrombocytopenia (HIT) - Approved in October 2020 DTC
|
|||||
Superficial Vein Thrombosis
Approved as Hospital Only for Superficial Vein Thrombosis in July 2021 Drugs and Therapeutics Committee. |
|||||
RIVAROXABAN (other uses)
|
|||||
Venous Thrombo-Embolism (VTE) and prevention of VTE recurrence in paediatric patients (September-2021)
Approved by DTC as Hospital Only for Superficial Vein Thrombosis in paediatric patients |
|||||
Superficial Vein Thrombosis (SVT) (July 2021)
Rivaroxaban 10mg tablets Approved by the DTC as Hospital Only for treatment of Superficial Vein Thrombosis in adult patients. |
|||||
Anticoagulation Contacts
Scroll down for links to documents on the fileshare |
|||||
Oral tablet | |||||
Rivaroxaban (Non-proprietary) | |||||
Xarelto (Bayer Plc) | |||||
streptokinase | Hospital Only | ||||
Streptokinase
This is a second line agent - please consider use of first line agent such as tenectoplase or alteplase depending on the indication - see seperate monograph for more information. |
|||||
Powder for solution for infusion | |||||
Streptokinase (Non-proprietary) | |||||
ticagrelor |
NICE TA236 NICE TA420 |
||||
Orodispersible tablet | |||||
Brilique (AstraZeneca UK Ltd) | |||||
Oral tablet | |||||
Brilique (AstraZeneca UK Ltd) | |||||
tinzaparin sodium | On Formulary | ||||
LMWH Shared Care Guideline
LMWH Shared Care Guideline |
|||||
GUIDELINES
See below for links to guidelines |
|||||
MEMO regarding Tinzaparin Guidelines for Obstetric Patients
|
|||||
Transfer of Care document - Treatment of PE in COVID patients
see attached document |
|||||
Anticoagulation Contacts
Scroll down for links to documents on the fileshare |
|||||
Peri-Operative Management of Oral Anticoagulation
Peri-Operative Management of Oral Anticoagulation |
|||||
Solution for injection | |||||
Tinzaparin sodium (Non-proprietary) | |||||
urokinase | On Formulary | ||||
UROKINASE
Unblocking catheters: |
|||||
Powder for solution for injection | |||||
Syner-KINASE (Syner-Med (Pharmaceutical Products) Ltd) | |||||
warfarin sodium | On Formulary | ||||
GUIDELINES/COUNSELLING CHECKLIST
See below for links to guidelines/counselling checklist |
|||||
Warfarin Management
Warfarin management |
|||||
Warfarin
Liquid not stocked. |
|||||
Anticoagulation Contacts
Scroll down for links to documents on the fileshare |
|||||
Oral suspension | |||||
Warfarin sodium (Non-proprietary) | On Formulary | ||||
Anticoagulation intranet page
Scroll down for links to documents on the fileshare |
|||||
Warfarin initiation
see attached |
|||||
Warfarin
Liquid not stocked. |
|||||
Oral tablet | |||||
Warfarin sodium (Non-proprietary) | |||||
Cardiovascular system / Oedema | |||||
amiloride hydrochloride | On Formulary | ||||
AMILORIDE HYDROCHLORIDE
Usually in conjunction with furosemide (co-amilofruse) to maintain K+ while on diuretic treament. |
|||||
Oral solution | |||||
Amiloride hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Amiloride hydrochloride (Non-proprietary) | |||||
amiloride with bumetanide | Off Formulary | ||||
Oral tablet | |||||
Amiloride with bumetanide (Non-proprietary) | |||||
bumetanide | On Formulary | ||||
BUMETANIDE
. |
|||||
Oral solution | |||||
Bumetanide (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Bumetanide (Non-proprietary) | |||||
chlortalidone | Off Formulary | ||||
Oral tablet | |||||
Chlortalidone (Non-proprietary) | |||||
Hylaton (Morningside Healthcare Ltd) | |||||
co-amilofruse | On Formulary | ||||
Oral tablet | |||||
Co-amilofruse (Non-proprietary) | |||||
Frumil (Sanofi) | |||||
diamorphine hydrochloride | |||||
National supply shortage of Diamorphine 5mg and 10mg Injections
The trust has received notification from the Department of Health & Social Care regarding a national supply shortage of Diamorphine 5mg and 10mg Injections. This shortage is anticipated to last until summer 2020. Please see the memo attached for further information for this drug shortage. |
|||||
Powder for solution for injection | |||||
Diamorphine hydrochloride (Non-proprietary) | |||||
National supply shortage of Diamorphine 5mg and 10mg Injections
The trust has received notification from the Department of Health & Social Care regarding a national supply shortage of Diamorphine 5mg and 10mg Injections. This shortage is anticipated to last until summer 2020. Please see the memo attached for further information for this drug shortage. |
|||||
furosemide | On Formulary | ||||
FUROSEMIDE
First line for treating fluid accumulation associtated with heart failure.
|
|||||
Oral solution | |||||
Furosemide (Non-proprietary) | On Formulary | ||||
Agreed standard strength for paediatrics
Furosemide 40mg/5ml should be used in adults only 50mg/5ml should be used for all paediatric doses 1mg or greater 20mg/5ml is reserved for Neonatal doses <1mg |
|||||
Frusol (Rosemont Pharmaceuticals Ltd) | |||||
Solution for injection | |||||
Furosemide (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Furosemide (Non-proprietary) | |||||
furosemide with triamterene | Off Formulary | ||||
mannitol | Hospital Only |
NICE TA266 |
|||
Osmohale Inhalation Powde (Mannitol) challenge to diagnose bronchial hyper-responsiveness (February 2023)
Mannitol was approved at NEL FPG as a third line option to histamine for aiding the diagnosis of bronchial hyper-responsiveness in adults where other diagnostics had been inconclusive, as an indirect challenge test. |
|||||
Infusion | |||||
Mannitol (Non-proprietary) | |||||
Inhalation powder | |||||
Mannitol (Non-proprietary) | |||||
Bronchitol (Chiesi Ltd) | |||||
metolazone | On Formulary | ||||
METOLAZONE
If metolazone available: |
|||||
Switching to the UK licensed preparation of Xaqua®(metolazone) 5mg tablets, May 2023
The Trust switched to the UK licensed preparation of Xaqua®(metolazone) 5mg tablets for all areas across the Trust. |
|||||
Metolazone caution with loop diuretics
Metolazone is a potent diuretic and when used with loop diuretics can cause a dramatic diuresis and disturbance to fluid balance and electrolytes due to sequential blockade of the nephron. Patients must be closely monitored and this combination should only be initiated by specialists with experience of using this combination e.g. cardiology or renal teams. Any patient discharged on the combination should have an outpatient follow-up appointment within two weeks. NOTE: Unlicensed |
|||||
Oral tablet | |||||
Metolazone (Non-proprietary) | |||||
Xaqua (Renascience Pharma Ltd) | |||||
spironolactone with furosemide | Off Formulary | ||||
torasemide | Off Formulary | ||||
Oral tablet | |||||
Torasemide (Non-proprietary) | |||||
Torem (Viatris UK Healthcare Ltd) | |||||
triamterene | Off Formulary | ||||
triamterene with chlortalidone | Off Formulary | ||||
Oral tablet | |||||
Triamterene with chlortalidone (Non-proprietary) | |||||
xipamide | Off Formulary | ||||
Oral tablet | |||||
Diurexan (Viatris UK Healthcare Ltd) | |||||
Cardiovascular system / Ascites | |||||
chlortalidone | Off Formulary | ||||
Oral tablet | |||||
Chlortalidone (Non-proprietary) | |||||
Hylaton (Morningside Healthcare Ltd) | |||||
co-amilozide | Off Formulary | ||||
Oral tablet | |||||
Co-amilozide (Non-proprietary) | |||||
spironolactone | On Formulary | ||||
SPIRONOLACTONE
Hypertension: Consider further diuretic therapy with low-dose spironolactone (25 mg once daily) if the blood potassium level is 4.5 mmol/l or lower. Use particular caution in people with a reduced estimated glomerular filtration rate because they have an increased risk of hyperkalaemia. NICE CG 127 |
|||||
Oral solution | |||||
Spironolactone (Non-proprietary) | |||||
Oral tablet | |||||
Spironolactone (Non-proprietary) | |||||
Aldactone (Pfizer Ltd) | |||||
Cardiovascular system / Hyperlipidaemia | |||||
acipimox | Off Formulary | ||||
Oral capsule | |||||
Olbetam (Pfizer Ltd) | |||||
alirocumab | Hospital Only |
NICE TA393 |
|||
ALIROCUMAB
Approved for use in accordance with NICE TA393 .ONLY TO BE PRESCRIBED AT BARTS HEART CENTRE UNDER SPECIALIST ADVICE OF LIPID CLINIC. |
|||||
Solution for injection | |||||
Praluent (Sanofi) | |||||
atorvastatin | On Formulary | ||||
ATORVASTATIN
First line for secondary and primary prevention - dosing as per NICE guidance.
Lipid modification guidelines |
|||||
Chewable tablet | |||||
Lipitor (Viatris UK Healthcare Ltd) | |||||
Oral suspension | |||||
Atorvastatin (Non-proprietary) | |||||
Oral tablet | |||||
Atorvastatin (Non-proprietary) | |||||
Lipitor (Viatris UK Healthcare Ltd) | |||||
bempedoic acid | On Formulary |
NICE TA694 |
|||
Oral tablet | |||||
Nilemdo (Daiichi Sankyo UK Ltd) | |||||
bempedoic acid with ezetimibe | On Formulary |
NICE TA694 |
|||
Oral tablet | |||||
Nustendi (Daiichi Sankyo UK Ltd) | |||||
bezafibrate | On Formulary | ||||
Modified-release tablet | |||||
Bezalip Mono (Teva UK Ltd) | |||||
Lipozate (Noumed Life Sciences Ltd) | |||||
Oral tablet | |||||
Bezafibrate (Non-proprietary) | |||||
Bezalip (Teva UK Ltd) | |||||
ciprofibrate | Off Formulary | ||||
Oral tablet | |||||
Ciprofibrate (Non-proprietary) | |||||
colesevelam hydrochloride | On Formulary | ||||
COLESEVELAM HYDROCHLORIDE
Second line bile acid sequestrant if colestyramine not tolerated. |
|||||
Oral tablet | |||||
Colesevelam hydrochloride (Non-proprietary) | |||||
Cholestagel (Neon Healthcare Ltd) | |||||
colestipol hydrochloride | |||||
Oral tablet | |||||
Colestipol hydrochloride (Non-proprietary) | |||||
colestyramine | On Formulary | ||||
COLESTYRAMINE
First line option as a bile acid sequestrant. |
|||||
Powder for oral suspension | |||||
Colestyramine (Non-proprietary) | |||||
Questran (Neon Healthcare Ltd) | |||||
Questran Light (Neon Healthcare Ltd) | |||||
evinacumab | |||||
Solution for infusion | |||||
Evkeeza (Ultragenyx UK Ltd) | |||||
evolocumab | Hospital Only |
NICE TA394 |
|||
Evolocumab
Approved for use in accordance with NICE TA394. ONLY TO BE PRESCRIBED AT BARTS HEART CENTRE UNDER SPECIALIST ADVICE OF LIPID CLINIC. |
|||||
Solution for injection | |||||
Repatha SureClick (Amgen Ltd) | On Formulary | ||||
ezetimibe | On Formulary |
NICE TA385 |
|||
Oral tablet | |||||
Ezetimibe (Non-proprietary) | |||||
Ezetrol (Organon Pharma (UK) Ltd) | |||||
fenofibrate | On Formulary | ||||
FENOFIBRATE
For raised triglycerides. |
|||||
Oral tablet | |||||
Fenofibrate (Non-proprietary) | |||||
Supralip (Viatris UK Healthcare Ltd) | |||||
Oral capsule | |||||
Fenofibrate (Non-proprietary) | |||||
Lipantil Micro (Viatris UK Healthcare Ltd) | |||||
fluvastatin | Off Formulary | ||||
Modified-release tablet | |||||
Fluvastatin (Non-proprietary) | |||||
Oral capsule | |||||
Fluvastatin (Non-proprietary) | |||||
gemfibrozil | On Formulary | ||||
Oral tablet | |||||
Gemfibrozil (Non-proprietary) | |||||
Lopid (Pfizer Ltd) | |||||
Oral capsule | |||||
Lopid (Pfizer Ltd) | |||||
icosapent ethyl | On Formulary |
NICE TA805 |
|||
Oral capsule | |||||
Vazkepa (Amarin Pharmaceuticals Ireland Ltd) | |||||
inclisiran | On Formulary |
NICE TA733 |
|||
Primary hypercholesterolaemia or mixed dyslipidaemia
Hospital prescribing via NHSE reimbursement- reviewed April 2022 DTC. |
|||||
Solution for injection | |||||
Leqvio (Novartis Pharmaceuticals UK Ltd) | |||||
lomitapide | Off Formulary | ||||
Oral capsule | |||||
Lojuxta (Chiesi Ltd) | |||||
nicotinic acid | Off Formulary | ||||
Oral capsule | |||||
Nicotinic acid (Non-proprietary) | |||||
omega-3-acid ethyl esters | On Formulary | ||||
Oral capsule | |||||
Omega-3-acid ethyl esters (Non-proprietary) | |||||
A1 Omega (TriOn Pharma Ltd) | |||||
AceOmeg (Essential-Healthcare Ltd) | |||||
Teromeg (Advanz Pharma) | |||||
pravastatin sodium | On Formulary | ||||
Oral tablet | |||||
Pravastatin sodium (Non-proprietary) | |||||
rosuvastatin | On Formulary | ||||
Oral tablet | |||||
Rosuvastatin (Non-proprietary) | |||||
Crestor (AstraZeneca UK Ltd) | |||||
Oral capsule | |||||
Rosuvastatin (Non-proprietary) | |||||
simvastatin | On Formulary | ||||
Simvastatin
Please note: Simvastatin 80mg are non-formulary. |
|||||
Oral suspension | |||||
Simvastatin (Non-proprietary) | On Formulary | ||||
SIMVASTATIN
First line statin for reduction of total cholesterol. |
|||||
Simvastatin bulletin
see attached |
|||||
Oral tablet | |||||
Simvastatin (Non-proprietary) | |||||
Zocor (Organon Pharma (UK) Ltd) | |||||
simvastatin with ezetimibe | Off Formulary | ||||
Oral tablet | |||||
Simvastatin with ezetimibe (Non-proprietary) | |||||
Inegy (Organon Pharma (UK) Ltd) | |||||
volanesorsen |
NICE HST13 |
||||
Solution for injection | |||||
Waylivra (Swedish Orphan Biovitrum Ltd) | |||||
Cardiovascular system / Bleeding disorders | |||||
emicizumab | Hospital Only | ||||
EMICIZUMAB
Contact Haemophilia Department at Royal London Hospital for supply |
|||||
Solution for injection | |||||
Hemlibra (Roche Products Ltd) | |||||
tranexamic acid | On Formulary | ||||
Solution for injection | |||||
Tranexamic acid (Non-proprietary) | Hospital Only | ||||
Guidelines for management of bleeding with NOACs - 2016
see attached |
|||||
Cyklokapron (Pfizer Ltd) | On Formulary | ||||
Guidelines for management of bleeding with NOACs - 2016
see attached |
|||||
Oral tablet | |||||
Tranexamic acid (Non-proprietary) | |||||
Cyklokapron (Viatris UK Healthcare Ltd) | |||||
Cardiovascular system / Coagulation factor deficiencies | |||||
dried prothrombin complex | Hospital Only | ||||
Octaplex Guidelines
|
|||||
Guidelines for management of bleeding with NOACs - 2016
|
|||||
Availability of haemostatic agents across Barts Health sites
https://weshare.bartshealth.nhs.uk/download.cfm?doc=docm93jijm4n12106&ver=33132 |
|||||
Powder and solvent for solution for injection | |||||
Beriplex P/N (CSL Behring UK Ltd) | |||||
Powder and solvent for solution for infusion | |||||
Octaplex (Octapharma Ltd) | |||||
factor IX [Specialist drug] | Hospital Only | ||||
FACTOR IX FRACTION, DRIED
Contact Haemophilia Department at Royal London Hospital for supply |
|||||
Powder and solvent for solution for injection | |||||
Alprolix (Swedish Orphan Biovitrum Ltd) | |||||
Haemonine (Grifols UK Ltd) | |||||
Idelvion (CSL Behring UK Ltd) | |||||
Refixia (Novo Nordisk Ltd) | |||||
Replenine-VF (Bio Products Laboratory Ltd) | |||||
Rixubis (Takeda UK Ltd) | |||||
Powder and solvent for solution for infusion | |||||
BeneFIX (Pfizer Ltd) | |||||
factor VIII fraction, dried [Specialist drug] | Hospital Only | ||||
FACTOR VIII FRACTION, DRIED
Contact Haemophilia Department at Royal London Hospital for supply |
|||||
Powder and solvent for solution for injection | |||||
Factor VIII fraction, dried (Non-proprietary) | |||||
Advate (Takeda UK Ltd) | |||||
Adynovi (Takeda UK Ltd) | |||||
Elocta (Swedish Orphan Biovitrum Ltd) | |||||
Esperoct (Novo Nordisk Ltd) | |||||
Haemoctin (Grifols UK Ltd) | |||||
NovoEight (Novo Nordisk Ltd) | |||||
Nuwiq (Octapharma Ltd) | |||||
Obizur (Takeda UK Ltd) | |||||
Octanate LV (Octapharma Ltd) | |||||
ReFacto (Pfizer Ltd) | |||||
Voncento (CSL Behring UK Ltd) | |||||
Powder and solvent for solution for infusion | |||||
Advate (Takeda UK Ltd) | |||||
Wilate 1000 (Octapharma Ltd) | |||||
Wilate 500 (Octapharma Ltd) | |||||
factor VIII inhibitor bypassing fraction [Specialist drug] | Hospital Only | ||||
Powder and solvent for solution for infusion | |||||
FEIBA Imuno (Takeda UK Ltd) | |||||
factor VIIa (recombinant) | Hospital Only | ||||
FACTOR VIIa (RECOMBINANT)
Off-license use for life-threatening bleeding in non-haemophilliac patients (decision made jointly by consultant anaesthetist/surgeon/physician AND consultant haematologist) |
|||||
Availability of haemostatic agents across Barts Health sites
https://weshare.bartshealth.nhs.uk/download.cfm?doc=docm93jijm4n12106&ver=33132 |
|||||
Powder and solvent for solution for injection | |||||
Cevenfacta (LFB Biopharmaceuticals Ltd) | |||||
NovoSeven (Novo Nordisk Ltd) | |||||
factor XIII A-subunit (recombinant) [Specialist drug] | |||||
Powder and solvent for solution for injection | |||||
NovoThirteen (Novo Nordisk Ltd) | |||||
factor XIII fraction, dried [Specialist drug] | Hospital Only | ||||
FACTOR XIII FRACTION, DRIED
Contact Haemophilia Department at Royal London Hospital for supply |
|||||
Powder and solvent for solution for injection | |||||
Fibrogammin P (CSL Behring UK Ltd) | |||||
fibrinogen, dried [Specialist drug] | Hospital Only | ||||
Availability of haemostatic agents across Barts Health sites
https://weshare.bartshealth.nhs.uk/download.cfm?doc=docm93jijm4n12106&ver=33132 |
|||||
Powder for solution for infusion | |||||
Riastap (CSL Behring UK Ltd) | |||||
Powder and solvent for solution for infusion | |||||
FibCLOT (LFB Biopharmaceuticals Ltd) | |||||
Fibryga (Octapharma Ltd) | |||||
fresh frozen plasma | Hospital Only | ||||
Infusion | |||||
OctaplasLG (Octapharma Ltd) | |||||
protein C concentrate [Specialist drug] | Hospital Only | ||||
Powder and solvent for solution for injection | |||||
Ceprotin (Takeda UK Ltd) | |||||
von Willebrand factor [Specialist drug] | |||||
Powder and solvent for solution for injection | |||||
Veyvondi (Takeda UK Ltd) | Hospital Only | ||||
Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease
Available for use under Clinical Commissioning Policy: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease |
|||||
Willfact (LFB Biopharmaceuticals Ltd) | |||||
Cardiovascular system / Subarachnoid haemorrhage | |||||
nimodipine | Hospital Only | ||||
Solution for infusion | |||||
Nimotop (Bayer Plc) | On Formulary | ||||
Oral tablet | |||||
Nimotop (Bayer Plc) | |||||
Cardiovascular system / Heart failure | |||||
Levosimendan | Hospital Only | ||||
levosimendan in treatment of acute heart failure
For initiation under direction of heart failure consultant - review monograph for dosing advice - NOTE do not give loading dose. |
|||||
bendroflumethiazide | On Formulary | ||||
Oral tablet | |||||
Bendroflumethiazide (Non-proprietary) | |||||
bisoprolol fumarate | On Formulary | ||||
BISOPROLOL FUMARATE
First-line for heart failure, atrial fibrillation, secondary prevention of MI and stable angina. https://www.nice.org.uk/guidance/ng136 https://www.nice.org.uk/guidance/ng185 |
|||||
Oral tablet | |||||
Bisoprolol fumarate (Non-proprietary) | |||||
Cardicor (Merck Serono Ltd) | |||||
candesartan cilexetil | On Formulary | ||||
CANDESARTAN CILEXETIL
Can be used if intolerant to ACE Inhibitor - cough for instance. Can be used for Heart Failure, post-MI or hypertension Secondary prevention of MI Guidelines |
|||||
Oral tablet | |||||
Candesartan cilexetil (Non-proprietary) | |||||
Amias (Neon Healthcare Ltd) | |||||
captopril | On Formulary | ||||
Oral solution | |||||
Captopril (Non-proprietary) | |||||
Oral tablet | |||||
Captopril (Non-proprietary) | |||||
chlortalidone | Off Formulary | ||||
Oral tablet | |||||
Chlortalidone (Non-proprietary) | |||||
Hylaton (Morningside Healthcare Ltd) | |||||
co-amilozide | Off Formulary | ||||
Oral tablet | |||||
Co-amilozide (Non-proprietary) | |||||
co-flumactone | Off Formulary | ||||
dapagliflozin | On Formulary |
NICE TA288 NICE TA390 NICE TA418 NICE TA679 NICE TA902 NICE TA775 |
|||
NICE TA 902 - September 2023 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Dapagliflozin approved at NEL FPG for treating chronic heart failure with preserved or mildly reduced ejection fraction in line with NICE TA. |
|||||
Oral tablet | |||||
Forxiga (AstraZeneca UK Ltd) | |||||
digoxin | On Formulary | ||||
Oral solution | |||||
Digoxin (Non-proprietary) | |||||
Solution for injection | |||||
Digoxin (Non-proprietary) | Hospital Only | ||||
Solution for infusion | |||||
Digoxin (Non-proprietary) | |||||
Oral tablet | |||||
Digoxin (Non-proprietary) | |||||
empagliflozin | On Formulary |
NICE TA390 NICE TA336 NICE TA773 NICE TA929 NICE TA942 |
|||
NICE TA 929 - December 2023 - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Empagliflozin approved at NEL FPG for treating chronic heart failure with preserved or mildly reduced ejection fraction
Formulary Status: Amber – To be initiated by or on the recommendation of a specialist |
|||||
September 2024, Empaglifozin for the treatment of Type 2 Diabetes Mellitus in Children and Young People
Empaglifozin approved at NEL FPG for the treatment of Type 2 Diabetes Mellitus in Children and Young People. First line SGLT2 Inhibitor in line with NICE Guidance (NG18)
Formulary Status: Amber – specialist initiated |
|||||
Empagliflozin- Treatment of symptomatic chronic heart failure with reduced ejection fraction as per NICE TA 773
Approved at DTC July 2022 for the treatment of symptomatic chronic heart failure with reduced ejection fraction |
|||||
NICE TA 942 - March 2024 - Empagliflozin for treating chronic kidney disease
Empagliflozin Approved at NEL FPG for treating chronic kidney disease
Formulary Status: Amber – To be initiated by or on the recommendation of a specialist |
|||||
Oral tablet | |||||
Jardiance (Boehringer Ingelheim Ltd) | |||||
enalapril maleate | On Formulary | ||||
Oral solution | |||||
Enalapril maleate (Non-proprietary) | |||||
Oral tablet | |||||
Enalapril maleate (Non-proprietary) | |||||
Innovace (Organon Pharma (UK) Ltd) | |||||
enoximone | Hospital Only | ||||
Solution for injection | |||||
Perfan (Macure Pharma UK Ltd) | |||||
eplerenone | On Formulary | ||||
EPLERENONE
Eplerenone is used second-line for both heart failure and hypertension if spironolactone not tolerated. |
|||||
Oral tablet | |||||
Eplerenone (Non-proprietary) | |||||
Inspra (Viatris UK Healthcare Ltd) | |||||
fosinopril sodium | Off Formulary | ||||
Oral tablet | |||||
Fosinopril sodium (Non-proprietary) | |||||
glyceryl trinitrate | On Formulary | ||||
Transdermal preparations
Prevention of thromobophlebitis in patients requiring emergency parenteral nutrition via peripheral line ('off-label'): apply one (5mg/24hr) patch distal to the venflon |
|||||
GLYCERYL TRINITRATE
Heart Failure guidelines
|
|||||
Sublingual tablet | |||||
Glyceryl trinitrate (Non-proprietary) | |||||
Sublingual spray | |||||
Glyceryl trinitrate (Non-proprietary) | |||||
Nitrolingual (Beaumont Pharma Ltd) | |||||
Solution for infusion | |||||
Glyceryl trinitrate (Non-proprietary) | |||||
Note:
Hospital Only |
|||||
Nitronal (Beaumont Pharma Ltd) | |||||
Transdermal patch | |||||
Deponit (Forum Health Products Ltd) | |||||
Minitran (Viatris UK Healthcare Ltd) | |||||
Rectal ointment | |||||
Rectogesic (Kyowa Kirin International UK NewCo Ltd) | |||||
hydralazine hydrochloride | On Formulary | ||||
HYDRALAZINE HYDROCHLORIDE
IV FORMULATION IS FOR HOSPITAL USE ONLY |
|||||
Powder for solution for injection | |||||
Hydralazine hydrochloride (Non-proprietary) | |||||
Oral tablet | |||||
Hydralazine hydrochloride (Non-proprietary) | |||||
Apresoline (Advanz Pharma) | |||||
isosorbide dinitrate | On Formulary | ||||
Isosorbide dinitrate in heart failure
Isosorbide dinitrate can be used for treatment of heart failure - usually in combination with hydralazine and usually in those unable to tolerate ACEi due to renal imparment. |
|||||
Modified-release tablet | |||||
Isoket Retard (Forum Health Products Ltd) | |||||
Solution for injection | |||||
Isosorbide dinitrate (Non-proprietary) | |||||
Isoket (Forum Health Products Ltd) | |||||
Solution for infusion | |||||
Isosorbide dinitrate (Non-proprietary) | |||||
Oral tablet | |||||
Isosorbide dinitrate (Non-proprietary) | |||||
isosorbide mononitrate | On Formulary | ||||
ISOSORBIDE MONONITRATE
Heart Failure guidelines |
|||||
Modified-release tablet | |||||
Isotard XL (Evolan Pharma AB) | |||||
Modisal XL (Ennogen Pharma Ltd) | |||||
Relosorb XL (Relonchem Ltd) | |||||
Xismox XL (Genus Pharmaceuticals Ltd) | |||||
Modified-release capsule | |||||
Elantan LA (Forum Health Products Ltd) | |||||
Isodur XL (Galen Ltd) | |||||
Monomax SR (Martindale Pharmaceuticals Ltd) | |||||
Oral tablet | |||||
Isosorbide mononitrate (Non-proprietary) | |||||
ivabradine | On Formulary |
NICE TA267 |
|||
IVABRADINE
Heart failure: specialist initiation for NYHA II-IV patients in stable congestive heart failure (CHF):
Off license use for postural orthostatic tachycardia syndrome - under specialist initiation only. |
|||||
Oral tablet | |||||
Ivabradine (Non-proprietary) | |||||
Procoralan (Servier Laboratories Ltd) | |||||
lisinopril | On Formulary | ||||
LISINOPRIL
Heart Failure Guidelines
Secondary prevention of MI Guidelines |
|||||
Oral solution | |||||
Lisinopril (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Lisinopril (Non-proprietary) | |||||
Zestril (Atnahs Pharma UK Ltd) | |||||
losartan potassium | On Formulary | ||||
LOSARTAN POTASSIUM
|
|||||
Oral tablet | |||||
Losartan potassium (Non-proprietary) | |||||
Cozaar (Organon Pharma (UK) Ltd) | |||||
milrinone | On Formulary | ||||
Milrinone IV Monograph (Adult Critical Care Only)
For use in Adult Critical Care areas only. |
|||||
Solution for injection | |||||
Milrinone (Non-proprietary) | |||||
Solution for infusion | |||||
Milrinone (Non-proprietary) | |||||
Primacor (Sanofi) | |||||
nebivolol | On Formulary | ||||
NEBIVOLOL
Specialist initiation with PEFR monitoring in hospital. (NB: mild to moderate COPD is not a contraindication for use of other cardioselective beta blockers) |
|||||
Oral tablet | |||||
Nebivolol (Non-proprietary) | |||||
Nebilet (A. Menarini Farmaceutica Internazionale SRL) | |||||
perindopril arginine | Off Formulary | ||||
Oral tablet | |||||
Coversyl Arginine (Servier Laboratories Ltd) | |||||
perindopril erbumine | On Formulary | ||||
PERINDOPRIL ERBUMINE
Heart Failure Guidelines
|
|||||
Oral tablet | |||||
Perindopril erbumine (Non-proprietary) | |||||
prazosin | Off Formulary | ||||
Oral tablet | |||||
Prazosin (Non-proprietary) | |||||
Hypovase (Pfizer Ltd) | |||||
quinapril | Off Formulary | ||||
Oral tablet | |||||
Quinapril (Non-proprietary) | |||||
Accupro (Pfizer Ltd) | |||||
ramipril | On Formulary | ||||
RAMIPRIL
First-line ACEI for hypertension, heart failure, secondary prevention of MI. https://www.nice.org.uk/guidance/ng106 |
|||||
Oral solution | |||||
Ramipril (Non-proprietary) | On Formulary | ||||
RAMIPRIL
First-line ACEI for hypertension, heart failure, secondary prevention of MI. |
|||||
Oral tablet | |||||
Ramipril (Non-proprietary) | |||||
Tritace (Sanofi) | |||||
Oral capsule | |||||
Ramipril (Non-proprietary) | |||||
sacubitril with valsartan | On Formulary |
NICE TA388 |
|||
Sacubitril valsartan NICE TA 388
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction, NICE TA388: |
|||||
Oral tablet | |||||
Entresto (Novartis Pharmaceuticals UK Ltd) | |||||
sodium nitroprusside | Hospital Only | ||||
Powder and solvent for solution for infusion | |||||
Sodium nitroprusside (Non-proprietary) | |||||
spironolactone | On Formulary | ||||
SPIRONOLACTONE
Hypertension: Consider further diuretic therapy with low-dose spironolactone (25 mg once daily) if the blood potassium level is 4.5 mmol/l or lower. Use particular caution in people with a reduced estimated glomerular filtration rate because they have an increased risk of hyperkalaemia. NICE CG 127 |
|||||
Oral solution | |||||
Spironolactone (Non-proprietary) | |||||
Oral tablet | |||||
Spironolactone (Non-proprietary) | |||||
Aldactone (Pfizer Ltd) | |||||
valsartan | On Formulary | ||||
VALSARTAN
Last-line option post-MI Heart Failure Guidelines
https://www.nice.org.uk/guidance/ng106 Hypertension Guidelines https://pathways.nice.org.uk/pathways/hypertension Secondary prevention of MI Guidelines |
|||||
Oral solution | |||||
Diovan (Novartis Pharmaceuticals UK Ltd) | |||||
Oral tablet | |||||
Valsartan (Non-proprietary) | |||||
Oral capsule | |||||
Valsartan (Non-proprietary) | |||||
vericiguat | |||||
Oral tablet | |||||
Verquvo (Bayer Plc) | |||||
Cardiovascular system / Myocardial ischaemia | |||||
acebutolol | Off Formulary | ||||
Oral tablet | |||||
Acebutolol (Non-proprietary) | |||||
amlodipine | On Formulary | ||||
AMLODIPINE
First-line dihydropyridine calcium channel blocker for hypertension. Can be considered for stable angina. |
|||||
Oral suspension | |||||
Amlodipine (Non-proprietary) | Off Formulary | ||||
Liquid prep- hospital only
Liquid prep to be used on the advice of clinical pharmacologist |
|||||
Oral solution | |||||
Amlodipine (Non-proprietary) | |||||
Oral tablet | |||||
Amlodipine (Non-proprietary) | |||||
Istin (Viatris UK Healthcare Ltd) | |||||
aspirin | On Formulary | ||||
Aspirin
Should not routinely used for primary prevention of cardiovascular disease.
Aspirin has multiple indications, follow the links below for more information
|
|||||
Dispersible tablet | |||||
Aspirin (Non-proprietary) | |||||
Disprin (Reckitt Benckiser Healthcare (UK) Ltd) | |||||
Gastro-resistant tablet | |||||
Aspirin (Non-proprietary) | |||||
Nu-Seals (Alliance Pharmaceuticals Ltd) | |||||
Suppository | |||||
Aspirin (Non-proprietary) | |||||
Oral tablet | |||||
Aspirin (Non-proprietary) | |||||
atenolol | On Formulary | ||||
Oral solution | |||||
Atenolol (Non-proprietary) | |||||
Solution for injection | |||||
Tenormin (Atnahs Pharma UK Ltd) | Off Formulary | ||||
Oral tablet | |||||
Atenolol (Non-proprietary) | |||||
Tenormin (Atnahs Pharma UK Ltd) | |||||
bisoprolol fumarate | On Formulary | ||||
BISOPROLOL FUMARATE
First-line for heart failure, atrial fibrillation, secondary prevention of MI and stable angina. https://www.nice.org.uk/guidance/ng136 https://www.nice.org.uk/guidance/ng185 |
|||||
Oral tablet | |||||
Bisoprolol fumarate (Non-proprietary) | |||||
Cardicor (Merck Serono Ltd) | |||||
bivalirudin | Hospital Only | ||||
Heparin Induced Thrombocytopenia (HIT)
https://weshare.bartshealth.nhs.uk/haematology-immunology?media_item=16727&media_type=10#file-viewer |
|||||
Powder for solution for infusion | |||||
Bivalirudin (Non-proprietary) | |||||
cangrelor | Off Formulary | ||||
Powder for solution for injection | |||||
Kengrexal (Chiesi Ltd) | |||||
carvedilol | On Formulary | ||||
CARVEDILOL
Can be used as second-line beta blocker (after bisoprolol) for heart failure, atrial fibrillation, hypertension, secondary prevention of MI and stable angina. |
|||||
Oral tablet | |||||
Carvedilol (Non-proprietary) | |||||
diltiazem hydrochloride | On Formulary | ||||
DILTIAZEM HYDROCHLORIDE
|
|||||
Modified-release tablet | |||||
Diltiazem hydrochloride (Non-proprietary) | On Formulary | ||||
Retalzem (Kent Pharma (UK) Ltd) | |||||
Tildiem (Sanofi) | |||||
Tildiem Retard (Sanofi) | |||||
Zeyam (Ennogen Pharma Ltd) | |||||
Modified-release capsule | |||||
Adizem-SR (Napp Pharmaceuticals Ltd) | |||||
Adizem-XL (Napp Pharmaceuticals Ltd) | |||||
Angitil SR (Ethypharm UK Ltd) | |||||
Angitil XL (Ethypharm UK Ltd) | |||||
Slozem (Zentiva Pharma UK Ltd) | |||||
Tildiem LA (Sanofi) | |||||
Viazem XL (Thornton & Ross Ltd) | |||||
Zemtard XL (Galen Ltd) | |||||
eptifibatide | Hospital Only | ||||
Antiplatelet and eptifibatide advice in Acute Coronary Syndromes
Refer to local monograph for use in cath labs - Note unlicensed dosing of two loading doses (180mcg/kg) given 10 minutes apart with concomitent infusion 2microgram/kg/min usually for 6 hours post procedure or upto 24 hours if high thrombus burden. |
|||||
Solution for injection | |||||
Eptifibatide (Non-proprietary) | |||||
Solution for infusion | |||||
Eptifibatide (Non-proprietary) | |||||
felodipine | On Formulary | ||||
Modified-release tablet | |||||
Cardioplen XL (Chiesi Ltd) | |||||
Delofine XL (Morningside Healthcare Ltd) | |||||
Felendil XL (Teva UK Ltd) | |||||
Felotens XL (Thornton & Ross Ltd) | |||||
Neofel XL (Kent Pharma (UK) Ltd) | |||||
Parmid XL (Sandoz Ltd) | |||||
Pinefeld XL (Tillomed Laboratories Ltd) | |||||
Vascalpha (Accord-UK Ltd) | |||||
fondaparinux sodium | On Formulary | ||||
Fondaparinux in acute coronary syndrome
Fondaparinux is now the trusts formulary choice of anticoagulant in NSTEMI-ACS. Dose 2.5mg ONCE DAILY Mode of administration Subcutaneous If undergoing PCI Preferably undergo PCI 4 - 24 hours after receiving the last fondaparinux dose and use UFH as an adjunct as per current practice. USE ALTERNATIVE anticoagulant if patient has a pre existing medical condition requiring anticoagulation - i.e. AF, DVT, mechanical valve etc - use enoxaparin 1mg/kg twice daily (adjusted for renal function). To stop post angioplasty unless clinically indicated Platelet monitoring Not required Contra-indication CrCl <20mls/mins if known, and use UFH |
|||||
FONDAPARINUX SODIUM
For acute coronary syndrome |
|||||
Heparin Induced Thrombocytopenia (HIT)
https://weshare.bartshealth.nhs.uk/haematology-immunology?media_item=16727&media_type=10#file-viewer |
|||||
Solution for injection | |||||
Fondaparinux sodium (Non-proprietary) | On Formulary | ||||
Fondaparinux in acute coronary syndrome
Fondaparinux is now the trusts formulary choice of anticoagulant in NSTEMI-ACS. Dose 2.5mg ONCE DAILY Mode of administration Subcutaneous If undergoing PCI Preferably undergo PCI 4 - 24 hours after receiving the last fondaparinux dose and use UFH as an adjunct as per current practice. To stop post angioplasty unless clinically indicated Platelet monitoring Not required Contra-indication CrCl <20mls/mins if known, and use UFH |
|||||
Arixtra (Viatris UK Healthcare Ltd) | On Formulary | ||||
Fondaparinux in acute coronary syndrome
Fondaparinux is now the trusts formulary choice of anticoagulant in NSTEMI-ACS. Dose 2.5mg ONCE DAILY Mode of administration Subcutaneous If undergoing PCI Preferably undergo PCI 4 - 24 hours after receiving the last fondaparinux dose and use UFH as an adjunct as per current practice. To stop post angioplasty unless clinically indicated Platelet monitoring Not required Contra-indication CrCl <20mls/mins if known, and use UFH |
|||||
glyceryl trinitrate | On Formulary | ||||
Transdermal preparations
Prevention of thromobophlebitis in patients requiring emergency parenteral nutrition via peripheral line ('off-label'): apply one (5mg/24hr) patch distal to the venflon |
|||||
GLYCERYL TRINITRATE
Heart Failure guidelines
|
|||||
Sublingual tablet | |||||
Glyceryl trinitrate (Non-proprietary) | On Formulary | ||||
Sublingual spray | |||||
Glyceryl trinitrate (Non-proprietary) | On Formulary | ||||
Nitrolingual (Beaumont Pharma Ltd) | On Formulary | ||||
Solution for infusion | |||||
Glyceryl trinitrate (Non-proprietary) | On Formulary | ||||
Note:
Hospital Only |
|||||
Nitronal (Beaumont Pharma Ltd) | |||||
Note:
Hospital Only |
|||||
Transdermal patch | |||||
Deponit (Forum Health Products Ltd) | On Formulary | ||||
Minitran (Viatris UK Healthcare Ltd) | |||||
Rectal ointment | |||||
Rectogesic (Kyowa Kirin International UK NewCo Ltd) | |||||
ivabradine | On Formulary |
NICE TA267 |
|||
IVABRADINE
Heart failure: specialist initiation for NYHA II-IV patients in stable congestive heart failure (CHF):
Off license use for postural orthostatic tachycardia syndrome - under specialist initiation only. |
|||||
Oral tablet | |||||
Ivabradine (Non-proprietary) | |||||
Procoralan (Servier Laboratories Ltd) | |||||
metoprolol tartrate | On Formulary | ||||
METOPROLOL TARTRATE
Initiation for atrial fibrillation, hypertension, secondary prevention of MI, heart failure, stable angina. https://www.nice.org.uk/guidance/ng185 https://www.nice.org.uk/guidance/ng196 https://www.nice.org.uk/guidance/ng133 https://www.nice.org.uk/guidance/cg126
|
|||||
Solution for injection | |||||
Betaloc (Recordati Pharmaceuticals Ltd) | Hospital Only | ||||
Oral tablet | |||||
Metoprolol tartrate (Non-proprietary) | |||||
nadolol | Off Formulary | ||||
Oral tablet | |||||
Nadolol (Non-proprietary) | |||||
nicardipine hydrochloride | Off Formulary | ||||
Solution for infusion | |||||
Nicardipine hydrochloride (Non-proprietary) | Off Formulary | ||||
Oral capsule | |||||
Cardene (Laboratoire X.O) | |||||
nicorandil | On Formulary | ||||
NICORANDIL
Second-line for angina (after nitrates). |
|||||
Oral tablet | |||||
Nicorandil (Non-proprietary) | |||||
nifedipine | On Formulary | ||||
Leiomyoma pain
Nidfedipine 10-20mg daily or twice daily is used in dermatology for pain resulting from leiomyoma |
|||||
Modified-release tablet | |||||
Adalat LA (Bayer Plc) | On Formulary | ||||
Leiomyoma pain
Nidfedipine 10-20mg daily or twice daily is used in dermatology for pain resulting from leiomyoma |
|||||
Adanif XL (Advanz Pharma) | |||||
Adipine MR (Chiesi Ltd) | |||||
Adipine XL (Chiesi Ltd) | |||||
Dexipress MR (Dexcel-Pharma Ltd) | |||||
Fortipine LA (Advanz Pharma) | |||||
Neozipine XL (Kent Pharma (UK) Ltd) | |||||
Nifedipress MR (Dexcel-Pharma Ltd) | |||||
Tensipine MR (Genus Pharmaceuticals Ltd) | |||||
Valni Retard (Tillomed Laboratories Ltd) | |||||
Modified-release capsule | |||||
Coracten SR (Teofarma S.r.l.) | |||||
Coracten XL (Teofarma S.r.l.) | |||||
Oral drops | |||||
Nifedipine (Non-proprietary) | |||||
Oral capsule | |||||
Nifedipine (Non-proprietary) | |||||
perindopril erbumine with amlodipine | |||||
pindolol | Off Formulary | ||||
propranolol hydrochloride | On Formulary | ||||
PROPRANOLOL HYDROCHLORIDE
Phaechromocytoma (usually started 24 hours after Phenoxybenzamine) |
|||||
PROPRANOLOL for thyrotoxicosis
Symptomatic relief of thyrotoxicosis- |
|||||
Modified-release capsule | |||||
Bedranol SR (Almus Pharmaceuticals Ltd, Sandoz Ltd) | |||||
Propranolol
Whipps Cross: somatic manifestations of acute alcohol withdrawal- see alcohol dependance for more information |
|||||
Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Half Beta-Prograne (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Oral solution | |||||
Propranolol hydrochloride (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Propranolol hydrochloride (Non-proprietary) | |||||
ranolazine | On Formulary | ||||
RANOLAZINE
Third-line option for stable angina. |
|||||
Modified-release tablet | |||||
Ranolazine (Non-proprietary) | |||||
Ranexa (A. Menarini Farmaceutica Internazionale SRL) | On Formulary | ||||
timolol maleate | Off Formulary | ||||
Eye drops | |||||
Timolol maleate (Non-proprietary) | |||||
Eysano (Aspire Pharma Ltd) | |||||
Timoptol (Santen UK Ltd) | |||||
Tiopex (Thea Pharmaceuticals Ltd) | |||||
Once-daily preparations
Long acting preparations of timolol are used in dermatology for cutaneous haemangioma |
|||||
Eye gel | |||||
Timoptol-LA (Santen UK Ltd) | |||||
Oral tablet | |||||
Timolol maleate (Non-proprietary) | |||||
tirofiban | Hospital Only | ||||
Infusion | |||||
Tirofiban (Non-proprietary) | |||||
Aggrastat (Advanz Pharma) | |||||
Solution for infusion | |||||
Aggrastat (Advanz Pharma) | |||||
verapamil hydrochloride | On Formulary | ||||
VERAPAMIL HYDROCHLORIDE
For rate controlled angina. https://www.nice.org.uk/guidance/ng196 Stable angina |
|||||
Modified-release tablet | |||||
Half Securon (Viatris UK Healthcare Ltd) | |||||
Securon SR (Viatris UK Healthcare Ltd) | |||||
Vera-Til SR (Accord-UK Ltd, Tillomed Laboratories Ltd) | |||||
Verapress MR (Dexcel-Pharma Ltd) | |||||
Oral solution | |||||
Verapamil hydrochloride (Non-proprietary) | On Formulary | ||||
Solution for injection | |||||
Securon (Viatris UK Healthcare Ltd) | Hospital Only | ||||
Oral tablet | |||||
Verapamil hydrochloride (Non-proprietary) | |||||
Cardiovascular system / Acute coronary syndromes | |||||
alteplase | Hospital Only |
NICE TA264 |
|||
PE guidelines
See below for link to guidelines |
|||||
ALTEPLASE
For treatment of stroke and PE |
|||||
Thrombolysis with Alteplase
. |
|||||
Powder and solvent for solution for injection | |||||
Actilyse (Boehringer Ingelheim Ltd) | Hospital Only | ||||
Powder and solvent for solution for infusion | |||||
Actilyse (Boehringer Ingelheim Ltd) | Hospital Only | ||||
captopril | |||||
Oral solution | |||||
Captopril (Non-proprietary) | |||||
Oral tablet | |||||
Captopril (Non-proprietary) | |||||
clopidogrel | On Formulary |
NICE TA210 |
|||
Antiplatelet and eptifibatide advice in Acute Coronary Syndromes
|
|||||
CLOPIDOGREL
First-line monotherapy after acute phase for ischaemic stroke in absence of atrial fibrillation. Assess bleeding risk for co-prescription of PPIs. Commonly loaded with 600mg prior to coronary artery stenting (with or with out ACS) - NOTE this is an unlicensed dose Consider lansoprazole or H2 antagonists (ranitidine) as gastroprotection with clopidogrel treatment. |
|||||
Oral tablet | |||||
Clopidogrel (Non-proprietary) | |||||
Plavix (Sanofi) | |||||
dalteparin sodium | Off Formulary | ||||
Solution for injection | |||||
Fragmin (Pfizer Ltd) | |||||
enoxaparin sodium | On Formulary | ||||
LMWH Shared Care Guideline
LMWH Shared Care Guideline |
|||||
GUIDELINES
See below for links to guidelines |
|||||
Transfer of Care document - Treatment of PE in COVID patients
see attached |
|||||
Peri-operative management
Peri-operative management |
|||||
Anticoagulation Contacts
Scroll down for links to documents on the fileshare |
|||||
Solution for injection | |||||
Arovi (ROVI Biotech Ltd) | |||||
Clexane (Sanofi) | On Formulary | ||||
Anticoagulation intranet page
Scroll down for links to documents on the fileshare |
|||||
Enoxaparin shared care guidelines
|
|||||
Inhixa (Techdow Pharma England Ltd) | |||||
Ledraxen (Tetris Pharma Ltd) | |||||
glyceryl trinitrate | On Formulary | ||||
Transdermal preparations
Prevention of thromobophlebitis in patients requiring emergency parenteral nutrition via peripheral line ('off-label'): apply one (5mg/24hr) patch distal to the venflon |
|||||
GLYCERYL TRINITRATE
Heart Failure guidelines
|
|||||
Sublingual tablet | |||||
Glyceryl trinitrate (Non-proprietary) | On Formulary | ||||
Sublingual spray | |||||
Glyceryl trinitrate (Non-proprietary) | On Formulary | ||||
Nitrolingual (Beaumont Pharma Ltd) | On Formulary | ||||
Solution for infusion | |||||
Glyceryl trinitrate (Non-proprietary) | On Formulary | ||||
Note:
Hospital Only |
|||||
Nitronal (Beaumont Pharma Ltd) | |||||
Note:
Hospital Only |
|||||
Transdermal patch | |||||
Deponit (Forum Health Products Ltd) | On Formulary | ||||
Minitran (Viatris UK Healthcare Ltd) | |||||
Rectal ointment | |||||
Rectogesic (Kyowa Kirin International UK NewCo Ltd) | |||||
heparin (unfractionated) | On Formulary | ||||
Unfractionated Heparin (UFH): Monitoring in Adult Patients
See below |
|||||
Solution for injection | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: |
|||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: |
|||||
Guidelines for the Diagnosis, Investigation and Management of
Heparin-Induced Thrombocytopenia (HIT)
Guidelines for the Diagnosis, Investigation and Management of
Heparin-Induced Thrombocytopenia (HIT)
HIT Guidelines 2016 |
|||||
Infusion | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
Heparin dose and rate adjustment according to APTT
At legacy BLT: IV infusion: Draw up 40ml of 1000units in 1ml heparin into a syringe (40,000units in 40ml). Administer by continuous infusion according to the patient’s weight, at the rate as stated below: Weight Rate(2) - mls per hourof 1000units in 1ml concentration Greater than 90kg 1.7 81-90kg 1.6 71-80kg 1.4 61-70kg 1.2 51-60kg 1.0 41-50kg 0.8 |
|||||
Form unstated | |||||
Heparin (unfractionated) (Non-proprietary) | |||||
isosorbide dinitrate | Off Formulary | ||||
Isosorbide dinitrate in heart failure
Isosorbide dinitrate can be used for treatment of heart failure - usually in combination with hydralazine and usually in those unable to tolerate ACEi due to renal imparment. |
|||||
Modified-release tablet | |||||
Isoket Retard (Forum Health Products Ltd) | |||||
Solution for injection | |||||
Isosorbide dinitrate (Non-proprietary) | |||||
Isoket (Forum Health Products Ltd) | |||||
Solution for infusion | |||||
Isosorbide dinitrate (Non-proprietary) | |||||
Oral tablet | |||||
Isosorbide dinitrate (Non-proprietary) | |||||
isosorbide mononitrate | On Formulary | ||||
ISOSORBIDE MONONITRATE
Heart Failure guidelines |
|||||
Modified-release tablet | |||||
Isotard XL (Evolan Pharma AB) | |||||
Modisal XL (Ennogen Pharma Ltd) | |||||
Relosorb XL (Relonchem Ltd) | |||||
Xismox XL (Genus Pharmaceuticals Ltd) | |||||
Modified-release capsule | |||||
Elantan LA (Forum Health Products Ltd) | |||||
Isodur XL (Galen Ltd) | |||||
Monomax SR (Martindale Pharmaceuticals Ltd) | |||||
Oral tablet | |||||
Isosorbide mononitrate (Non-proprietary) | |||||
lisinopril | On Formulary | ||||
LISINOPRIL
Heart Failure Guidelines
Secondary prevention of MI Guidelines |
|||||
Oral solution | |||||
Lisinopril (Non-proprietary) | On Formulary | ||||
Oral tablet | |||||
Lisinopril (Non-proprietary) | |||||
Zestril (Atnahs Pharma UK Ltd) | |||||
perindopril arginine | Off Formulary | ||||
Oral tablet | |||||
Coversyl Arginine (Servier Laboratories Ltd) | |||||
perindopril erbumine | On Formulary | ||||
PERINDOPRIL ERBUMINE
Heart Failure Guidelines
|
|||||
Oral tablet | |||||
Perindopril erbumine (Non-proprietary) | |||||
prasugrel | On Formulary |
NICE TA317 |
|||
PRASUGREL
Specialist initiation for acute coronary syndrome - third line after other P2Y12 inhibitors not tolerated or unable to be used due to interactions.
|
|||||
Approved for neurovascular stenting for patients who are resistant to clopidogrel
Approved September DTC 2021 |
|||||
Oral tablet | |||||
Prasugrel (Non-proprietary) | |||||
Efient (Vygoris Ltd) | |||||
ramipril | On Formulary | ||||
RAMIPRIL
First-line ACEI for hypertension, heart failure, secondary prevention of MI. https://www.nice.org.uk/guidance/ng106 |
|||||
Oral solution | |||||
Ramipril (Non-proprietary) | On Formulary | ||||
RAMIPRIL
First-line ACEI for hypertension, heart failure, secondary prevention of MI. |
|||||
Oral tablet | |||||
Ramipril (Non-proprietary) | |||||
Tritace (Sanofi) | |||||
Oral capsule | |||||
Ramipril (Non-proprietary) | |||||
streptokinase | Hospital Only | ||||
Streptokinase
This is a second line agent - please consider use of first line agent such as tenectoplase or alteplase depending on the indication - see seperate monograph for more information. |
|||||
Powder for solution for infusion | |||||
Streptokinase (Non-proprietary) | |||||
tenecteplase | Hospital Only | ||||
September 2024, NICE TA 990 Tenecteplase for treating acute ischaemic stroke
Tenecteplase approved at NEL FPG for treating acute ischaemic stroke in line with NICE TA.
Formulary Status: Hospital Only |
|||||
Powder and solvent for solution for injection | |||||
Tenecteplase (Non-proprietary) | |||||
Metalyse (Boehringer Ingelheim Ltd) | On Formulary | ||||
Fibrinolysis with tenecteplase BHC Nov 2015
|
|||||
ticagrelor | On Formulary |
NICE TA236 NICE TA420 |
|||
Antiplatelet and eptifibatide advice in Acute Coronary Syndromes
|
|||||
Orodispersible tablet | |||||
Brilique (AstraZeneca UK Ltd) | |||||
Oral tablet | |||||
Brilique (AstraZeneca UK Ltd) | |||||
trandolapril | Off Formulary | ||||
Oral capsule | |||||
Trandolapril (Non-proprietary) | |||||
valsartan | On Formulary | ||||
VALSARTAN
Last-line option post-MI Heart Failure Guidelines
https://www.nice.org.uk/guidance/ng106 Hypertension Guidelines https://pathways.nice.org.uk/pathways/hypertension Secondary prevention of MI Guidelines |
|||||
Oral solution | |||||
Diovan (Novartis Pharmaceuticals UK Ltd) | |||||
Oral tablet | |||||
Valsartan (Non-proprietary) | |||||
Oral capsule | |||||
Valsartan (Non-proprietary) | |||||
Cardiovascular system / Cardiac arrest | |||||
adrenaline/epinephrine | On Formulary | ||||
MHRA Alert Oct 2019
The Medicines & Healthcare products Regulatory Agency (MHRA) has received reports of Emerade pens failing to activate. The product is not being recalled, instead the attached patient information should be given to patients who use this product. Further information on the alert can be found: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-emerade-150-300-and-500-microgram-solution-for-injection-in-pre-filled-syringe-mdr-57-08-19?utm_source=f03b2ee9-32c9-4c29-9dde-a224560325d3&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate Patients experiencing any problem with Emerade failing to activate should report this via the MHRA’s Yellow Card Scheme and keep the pen for further examination. |
|||||
Adrenaline auto-injector shortage
There is an on-going supply issue with Emerade devices, which is affecting the stock of all other brands of adrenaline auto-injectors.
Please refer to the below memo for further information. |
|||||
Solution for injection | |||||
Adrenaline/epinephrine (Non-proprietary) | On Formulary | ||||
EpiPen (Viatris UK Healthcare Ltd) | On Formulary | ||||
Jext (ALK-Abello Ltd) | On Formulary |